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CHAPTER I 
 
INTRODUCTION 
 
Genome-wide association studies (GWAS) have identified numerous single nucleotide 
polymorphisms (SNP) associated with a variety of clinic traits [1]. Unfortunately, a full 88% of 
significant GWAS findings are in non-coding regions of the genome [2], making the exact 
biological mechanism underlying the association unclear. However, it has been shown that trait-
associated SNPs are more likely to affect gene expression levels than non-trait associated SNPs 
[3] This effect – SNPs associating with differential gene expression levels – is termed expression 
quantitative trait loci or eQTL. There are two primary types of eQTL: cis and trans. Cis-eQTL 
are where the variant is within 500 kilobases (kb) of the gene that is differentially expressed. 
Trans-eQTL, on the other hand, are more than 500kb away from the differentially expressed 
gene, sometimes on entirely different chromosomes [4]. 
Most eQTL studies have focused on cis-eQTL for a variety of reasons. First, cis-eQTL 
have clear potential biological mechanisms. When a variant is located in a cis-regulatory region, 
it stands to reason that an allele change could alter the binding affinity of transcriptions factors 
resulting in differential expression. Other variants in non-coding portions of the gene could affect 
transcript stability again altering expression levels. Second, cis-eQTL are relatively easy to test. 
The relatively limited number of SNP-gene pairs allow for stringent, but not excessive, multiple 
testing penalties. Additionally, the number of tests is computationally tractable, especially 
compared to exhaustive testing for trans-eQTL which requires testing all possible combinations 
of SNPs and gene expression values. Further complicating matters, trans-eQTL have tended to 
have smaller effect sizes that are more variable across different tissue types than cis-eQTL [5]. 
Additionally trans-effects have been shown to replicate across populations less well than cis-
eQTL, thereby requiring large sample sizes in populations of homogenous descent [6].Finally, 
trans-eQTL lack clear biological explanations for mechanisms of effect. Although some have 
proposed that close 3-dimensional contact between SNPs and the differentially expressed gene 
(as measured through chromatin conformation) could explain this effect [7], this hypothesis has 
not been extensively tested and the prevalence of this effect is unclear. We propose an alternate  
A. 
2 
 
 
B. 
 
Figure 1. Study Rationale.  Panel A shows all human chromosomes and illustrates a SNP (blue 
arrow) that has an effect on the expression of the cis-gene (green boxes), and also affects 
expression of four trans-genes on other chromosomes (orange boxes). Panel B demonstrates our 
studies hypothesis that these trans-genes are part of a biological pathway – explaining a potential 
mechanism for the SNP’s trans-effects. 
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explanation that trans-eQTL may be operating through genetic pathways to alter gene 
expression.  
Figure 1 explains our general conceptual framework for this problem. When there is a 
known cis-eQTL (represented by the blue arrow – SNP- and cis-gene – green rectangle), it stands 
to reason that this gene may be connected to trans-genes whose differential expression is 
associated to the SNP in question. If this is the case, it is likely that the SNP may be associated to 
the entire pathway – not just the genes inside the pathway. In this work we selected known cis-
eQTL variants and tested them for association to differential expression of entire pathways. 
Given the general lack of replication and generalization of trans-effects, we performed both 
discovery and replication analyses in multiethnic cohorts. To further determine whether these 
effects act solely through the cis-eQTL gene (as is plausible in the hypothetical example) we also 
perform conditional analysis of each SNP-Pathway association, removing the effect of the 
expression of the cis-eQTL gene. Moreover we fully annotate all of our replicating SNPs with 
functional genomics data to further investigate potential effect mechanisms. 
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CHAPTER II 
 
BACKGROUND 
 
As described in the introduction, numerous single nucleotide polymorphisms have been 
associated with human traits. However to understand the mechanism behind those associations 
one needs to understand potential biological effects that can give rise to a disease state. 
Generically one can think of the following ways disease states can occur:  
1. Improper protein formation or modification (affecting function or stability) 
2. Improper trafficking or location of properly formed proteins 
3. Improper expression of proteins (too much, too little, or inappropriate timing of 
expression).  
To illustrate the first biological mechanism, SNPs in protein coding regions of the 
genome can alter the amino acid sequence of the protein perhaps affecting the proteins function 
or stability. Even intronic SNPs (i.e. non-coding variants) could be part of known splice site 
locations that alter exon arrangements again affecting the function or stability of the final protein 
product. For variants in unannotated regions of the genome, most have unknown function, but 
they likely contribute to the latter two potential molecular mechanisms underlying disease: 
improper trafficking or expression. In this work, we focus our attention on the third mechanism – 
altered gene expression. While some consider gene expression to mean the amount of fully 
functional protein product, in this work we refer to gene expression as the levels of RNA 
transcript in the cell. To better understand how single nucleotide polymorphisms can affect gene 
expression, we first need to understand how gene expression is measured and the basic biology 
behind normal gene expression. 
 
Measuring Gene Expression Levels 
 
RNA transcript abundance can be measured through a variety of experimental techniques. 
For high throughput, genome-wide assays, most experiments use microarray technologies or 
more recently RNA sequencing (RNA-seq). In both methods it is typical to amplify the transcript 
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abundance using either reverse transcription (making complementary DNA or cDNA) or 
antisense RNA amplification (making aRNA also known as complementary RNA or cRNA) [8]. 
Microarrays then hybridize these amplified sequences to labeled, preselected probes that are 
complementary to specific gene transcripts. Abundance of each transcript is measured base on 
the intensity of hybridization where higher intensity means more abundance of transcript. One 
disadvantage of this method is that it only captures transcripts included on the array. 
Additionally, variants located in the probe may artificially alter measured expression levels. In 
RNA sequencing, next generation sequencing technologies are used to sequence the amplified 
cDNA samples. Transcript abundance is usually inferred based on sequencing coverage, or read 
depth (i.e. how many copies of sequence map back to the original gene). Unlike microarrays, 
RNA-seq is agnostic in measuring each transcript, so the experiments are not limited to the 
probes used in the platform. Additionally, RNA-seq can identify specific transcript isoforms 
(differentially spliced transcripts – i.e. those with different numbers or ordering of exons).  
 
Defining Functional Elements and their Role in Mediating Gene Expression 
 
Transforming DNA into a protein product is a complicated process with strict regulation 
and numerous intermediate products. The expression of any single gene is dependent on cell 
type, temporal and biological conditions. For genes that are expressed, first the gene is 
transcribed into heterogeneous nuclear RNA (hnRNA) containing complete 3’ and 5’ 
untranslated regions, introns and exons. This hnRNA is processed into messenger RNA (mRNA) 
for transport outside of the nucleus by intron removal, appending a poly-adenine tail to the 3’ 
end, and addition of a 5’ methylguanosine cap. This mRNA can then be translated into a protein 
product by ribosomes outside of the nucleus. These protein products may be further modified 
into the final functional form of the protein. There are two clear biological routes to altered 
levels of RNA transcript abundance – 1) pre-transcription modifications affecting production of 
RNA products and 2) post-translational modifications that affect stability and therefore 
abundance of RNA transcript. 
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Pre-Transcriptional Regulation of Gene Expression 
There are a number of factors affecting whether and how a gene will be transcribed. First, 
the gene and its regulatory elements must be accessible to transcription machinery. Second, 
alterations to regulatory elements or availability of specific regulatory elements can alter 
transcription levels. The openness of DNA can be accessed experimentally using DNaseI 
hypersensitivity assays [9]. DNaseI is an enzyme that cleaves DNA at pyrimidine bases in both 
single and double stranded DNA. However this enzyme can only act on open regions of DNA 
where the specific nucleotide can be interrogated. Thus identifying locations susceptible to 
DNaseI cleavage is a good proxy for open regions of chromatin. 
Biological determination of DNA sequence availability to transcription machinery is 
primarily determined based on chromatin state. To have efficient packaging of DNA in a cell, 
DNA is wound around histone protein complexes to form a nucleosome. During replication, 
these nucleosomes can be further wound into fibers that are wound, compressed and coiled into 
chromatids. The tighter DNA is wound around the histone complexes, the less accessible the 
DNA sequence is for transcription. The levels of tightness of coiling around histones are 
determined by different types of modifications to the histone proteins. “Chromatin state” is 
therefore a qualitative descriptor of the types of histone modifications present and their effect on 
DNA accessibility.  
Additionally, chromatin state can be indicative of the function of different regions of 
DNA. For instance, a study in 2010 used Hidden Markov Models to identify specific 
combinations of histone modifications that correlated with specific types of functions [10]. This 
analysis found that methylation of various lysine residues on histone 3 was associated with 
promoter elements – the site of RNA transcription initiation. Other histone combinations were 
correlated with different functions in intergenic regions, specifically: enhancers and insulators. 
Enhancers and insulators interact with transcription machinery to increase or decrease 
transcription respectively. 
In regions that are open for transcription, different protein complexes or transcription 
factors bind to DNA to carry out transcription. Each transcription factor has slightly different 
regulatory processes dictating their effect. Thus knowledge of specific transcription factor 
binding sites can give insight into the patterns of expression of the gene. Typically transcription 
factors have a specific consensus sequence of nucleotide base pairs that correspond to the 
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physical connection between the transcription factor and the DNA sequence [11]. Sequence 
variation or nucleotide modifications in this region can alter the efficacy of transcription factor 
binding and therefore the amount of transcript produced.  
The final type of functional variation that can impact the efficacy of regulatory 
machinery is DNA methylation. Unlike histone methylation that modifies the histone protein, 
DNA methylation involves addition of a methyl group to specific nucleotides. This methylation 
typically occurs in regions enriched for cytosine and guanine content and are termed CpG 
islands. When these nucleotides are methylated they tend to inhibit transcription of the nearby 
gene. These regions can also affect chromatin structure, again impacting relative abundance of 
transcription. 
 
Post-Transcriptional Regulation of Gene Expression 
During post-transcriptional modification, intron regions are removed and exons are 
spliced back together. However, for many genes the precise number or ordering of exons 
retained vary leading those genes to produce multiple different transcripts or isoforms. This 
alternative splicing is known to be highly heritable and common [12]. These splice isoforms are 
expressed at different levels and experience degradation at different frequencies due to nonsense 
mediated decay or other factors impacting transcript stability. These variations can have an 
artificial impact on total mRNA levels for the gene as measured through microarrays because 
some isoforms may bind more or less well to the expression probe. Another post-transcriptional 
modification, polyadenylation of the pre-mRNA, can affect transcript levels through reduced 
transcript stability. 
 
Expression Quantitative Trait Loci 
 
Cis-eQTL , or SNPs associated to the expression of a gene that is within 500-1000kb 
have been widely studied in humans [5,13-19]. Many of these studies have focused on 
characterizing the biological effects of these SNPs while others have focused on associations to 
diseases and human health [20-23]. It has even been shown that many of the disease associated 
variants in the GWAS catalog are known eQTL [3].  
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It is relatively clear how these variants could act to alter gene expression. As described by 
the overview of functional elements, most of the functional elements affecting gene expression 
are located close to the gene being expressed (i.e. within 500-1000kb up or downstream of the 
gene).Given that knowledge, it is likely that the cis-eQTL, or a variant in linkage disequilibrium 
(LD), could disrupt transcription factor binding, CpG methylation signals, splice site junctions or 
the polyadenylation signal sequence. What is less clear is how variants further away (or even on 
a different chromosome) could impact gene expression levels. 
 
Trans-eQTL 
Trans-eQTL are defined as variants associating with gene expression levels of a gene 
more than 1Mb away from the variant. Typically these effects are smaller and replicate less well 
than cis-variants [5,24]. In general these types of association are tested far less commonly, likely 
due to the lack of a clear biological mechanism an the dramatic expansion of statistical tests 
required to detect these effects [25].  However they do account for a significant portion of the 
heritability of gene expression levels and tend to replicate only in similar tissue types [26]. 
Investigation of known trait or disease associated SNPs found enrichment for trans-eQTL and 
cis-eQTL over non-associated common variants. Many variants associated to the same 
phenotypic trait all acted as trans-eQTL for the same trans-gene/s [27]. Trans-eQTL have also 
been directly associated to human disease [28]. 
Interestingly many trans-eQTL co-localize in the genome. These eQTL hotspots were 
initially identified in model organisms [29,30], and have recently been replicated in humans [31]. 
It is hypothesized that these variants may act as master regulators [32,33], though others propose 
that these variants are acting through pathway-based mechanisms [34-37]. In one study of the 
proposed pathway effect, known trans-eQTL for the same SNP were tested using Gene Set 
Enrichment Analysis (GSEA) and found an abundance of known upstream transcriptional 
regulators [34]. Other studies have used pathways and interaction networks to try to determine 
the actual genes being directly regulated by the SNP (i.e. removing those genes whose 
association is mediated through the pathway) [36,37]. One other study has proposed a similar 
approach to our work, performing pathway analysis over all known eQTL for a given SNP using 
Ingenuity Pathway Analysis (IPA) – a proprietary data source. This study was performed on a 
superset of European samples contained in the HapMap project and was not replicated in any 
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other sample or population [35]. Importantly, this study had numerous limitations. The lack of 
replication, generalization and the use of proprietary software/knowledge sources severely limit 
the impact of this work. 
 
Controlling for Population Stratification in eQTL Studies 
Generalizability (i.e. replication of effect across multi-ethnic populations) is important to 
determine the extensibility of the observed effect. However, when performing analyses in 
multiethnic populations, it is important to control for the confounding effect population can play. 
It is well understood that different distributions in minor allele frequency and phenotypic 
outcomes among different populations can decrease power and lead to spurious associations 
[38]. It has been shown that amongst the HapMap II populations, between 17% and 29% of 
genes are differentially expressed when comparing one population to another [6]. Given the 
known allelic differences and this phenotypic difference, it is critical to correct for population 
stratification in expression studies using multiple populations. Many studies perform all quality 
control and analysis steps separately in each population [6]. However this can greatly reduce 
power due to the smaller sample sizes within each population. Other strategies include correcting 
admixed populations gene expression levels with principal components analysis [15]. Still others 
have further corrected the gene expression levels within populations to align all populations to a 
standard (and hence comparable) distribution [14]. This approach allows all populations to be 
combined and analyzed at the same time, thereby increasing power through larger sample size. 
This correction involves performing a normal quantile transformation to each gene within a 
single population. While there is data loss in terms of the true spacing between relative gene 
expression values, the method reduces the effect of outlier expression values, and sets all 
populations and genes to the same distribution allowing for a combined analysis. 
 
Approaches to Pathway Analysis 
 
There are multiple types of pathway analyses used in bioinformatics. Many studies use 
ontologic approaches to group differentially expressed genes according to their Gene Ontology 
(GO) functions [39]. Others use biological pathways and protein interaction knowledge bases 
such as, Reactome [40,41] or the Kyoto Encyclopedia of Genes and Genomes (KEGG) [42,43]. 
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Statistical analysis tends to use either over-representation analysis (ORA) or gene-set enrichment 
analysis (GSEA) Over-representation analysis essentially tests the hypothesis that there are more 
differentially expressed genes in a pathway or ontology group than expected by chance alone 
(typically determined through permutation testing [44]. Gene-set enrichment analysis is a more 
complicated approach that ranks genes from a given set (biological pathway, physical proximity, 
GO category, etc) based on the correlation of their expression with a particular phenotype. Under 
the null hypothesis that the pathway is unrelated to the phenotypic outcome, correlation values 
would be randomly distributed. GSEA uses a random walk algorithm to calculate an enrichment 
score that measures how overrepresented the set of genes are at either the top or bottom of the 
distribution. The significance of this enrichment score is determined through phenotypic 
permutation testing [45].  
What both ORA and GSEA fail to take into account is the organization of the gene 
sets/pathways and topology features of those networks. Essentially all genes are treated with 
equal weight where in true biological pathways some genes have more impact than others (e.g. 
may impact expression of many genes). Similarly, differential expression of subsets of genes 
may provide more evidence of dysregulation than others. For instance if a set of interacting 
genes are all differentially expressed this is more relevant biologically than if the differentially 
expressed genes are randomly distributed throughout the pathway. It is for these reasons that 
Signaling Pathway Impact Analysis (SPIA) was developed [46].  
 
Project Specific Data Sets and Tools 
 
International HapMap Project and the 1000 Genomes Project 
One hypothesis of genetic influences on complex traits is the common disease common 
variant hypothesis (CDCV). Essentially, if a disease is common within a population, it stands to 
reason that the genetic factors behind that disease would also common. In 2001 it was estimated 
that 10 million bases in the genome had common variation (alternate alleles at >1% frequency in 
the population) across the world human population [47]. While it was possible to interrogate 
some of this variation in regions of known interest, identifying candidate regions in an agnostic 
manner was not feasible due to sequencing cost and the burden of correction for the high number 
of statistical tests needed for single variant association. However, by understanding the process 
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by which genetic variation arises, it was determined that a much smaller subset of variants could 
be used to capture the broader common variation in the genome. 
Variation in the genome typically originates in singular mutation events on a common 
genetic background. Over generations this mutation can propagate through a population and 
become common. This SNP is associated with the other variants from the background sequence. 
This region, called a haplotype, is changed in sequence and length as further mutation or 
recombination events occur. Linkage disequilibrium (LD) describes this phenomenon of co-
inheritance of these alleles. Studies can then use variants that most precisely define the haplotype 
present (thereby tagging other variation in the region) for more efficient interrogation of the 
human genome. This approach has been widely used in genome-wide association studies. 
However, the amounts of LD present and even which SNPs tag the most variation differs by 
population. In 2003 the International HapMap Consortium was formed to create a human 
haplotype map for multiple ancestral populations [48]. 
The first phase of this project developed haplotype maps for four ancestral populations – 
specifically 30 trios (parents and one offspring, 90 individuals total) from the Yoruba in Ibadan, 
Nigeria (YRI), 30 trios from Utah (CEU), 45 unrelated Han Chinese from Beijing (CHB) and 45 
unrelated Japanese in Tokyo (JPT). The first phase genotyped common variation (minor allele 
frequency (MAF) > 5% in the population) every 5 kilobases (kb) [49]. The second phase of this 
project increased the density of variation to one SNP every kilobase, capturing approximately 
25-35% of common SNPs in the human genome [50]. The third phase of the project greatly 
increased the number of individuals and populations (1,184 individuals across 11 populations). 
Importantly, this project phase only captured approximately 1 million variants through 
genotyping technologies compared with the combined Phase I and II sequencing and genotyping 
efforts which measured over 3 million SNPs. The original four populations were included in the 
project (with new samples from these populations). Additional populations included: ASW – 
African Americans from the southwest United States; CHD – Chinese individuals in Denver, 
Colorado; GIH – Gujarati Indians from Houston, Texas; LWK – Luhya in Webuye, Kenya; 
MKK – Maasai in Kinyawa, Kenya; MXL – Mexican ancestry individuals from Los Angeles, 
California; TSI – Tuscans in Italy [51].  
Ultimately the success of the International HapMap Project and the GWAS it enabled, led 
the field to begin examination of low frequency and rare variation (minor allele found in <1% of 
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the population) through the 1000 Genomes Project. This project sought to identify haplotype 
information for all genetic variation (not just common variation as in HapMap) for variants with 
a minor allele frequency > 1%. Additionally the project catalogued rare variation (minor allele 
frequency down to 0.1%) in coding regions of the genome. Like Phase III of the HapMap 
Project, this project studied a larger set of populations pulled from five broad ancestral groups. 
Ultimately the project concluded that it had identified over 95% of all currently accessible 
variation in an individual’s genome [52]. In addition to the genetic data that these two projects 
produced, many of the individuals from the population had lymphoblastoid cell lines (LCLs) 
created through transformation of B-lymphocytes with Epstein Barr Virus (EBV). These cells are 
available for research and have been widely used in other large scale projects. 
 
Functional Variation Databases 
Following the completion of the Human Genome Project, it became obvious that 
identifying the function of the 3 billion bases was the next step forward for the field. This need 
created the Encyclopedia of DNA Elements Project (ENCODE) whose goal was to identify all 
functional elements in the human genome sequence [53]. In 2004, the pilot phase of this project 
started and focused on only 1% of the genome. The pilot phase sought to identify procedures and 
technologies that could be used to eventually interrogate the entire genome – developing new 
technologies where necessary. Ultimately the ENCODE consortium planned to identify the 
following types of functional elements in the genome: 
• Genes • Chromatin Modifications 
• Exons • Sites of Methylation 
• Origins of Replication • DNaseI Hypersensitive Sites 
• Replication Termination Locations • Promoters 
• Transcription Factor Binding Sites • Enhancers 
• Conserved Regions Across Species • Repressors/Silencers 
These features would be measured using a combination of transcript and chromatin 
immunoprecipitation microarray hybridization (ChIP-chip), other array based technologies (for 
methylation), and computational methods. 
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The pilot project of ENCODE was completed and published in 2007. These preliminary 
results showed that the genome is pervasively transcribed and revealed numerous details about 
regulatory elements and sequences affecting gene transcription [54]. With the knowledge and 
tools from the pilot project in hand, the project extended their analysis to the remainder of the 
genome. This vastly expanded analysis culminated in a coordinated release of 30 different 
publications highlighted in a special issue of Nature [55]. In total the final ENCODE project 
evaluated up to seven major types of functional variation (DNA methylation, open chromatin 
regions, RNA binding sites, RNA transcript sequences, ChIP-seq, histone modifications, and 
transcription factor binding sites) in more than 150 cell lines. Not all types of annotation are 
available for every cell line, so there is more work to be completed. 
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CHAPTER III 
 
METHODS 
 
Datasets 
 
Gene Expression  
Given that gene expression offers an important intermediate link between genetic 
variation and disease and is highly heritable, Barbara Stranger and others used the genetic 
variation present in HapMap and the accompanying cell lines to perform studies of eQTL in 
these populations [6]. In 2007, this group measured gene expression of lymphoblastoid cell lines 
from 270 Phase I and II HapMap samples using the Illumina whole-genome expression (WG-6 
version 1) array. This platform measured 47,294 probes, and after filtering probes that map to 
multiple positions in the genome, a total of 14,456 probes representing 13,643 genes remained. 
These data were made publically available through the Gene Expression Omnibus (GEO; Series 
Accession Number GSE6536; ref. 19). These data were further processed by Veyrieras et. al. 
2008 to remove known probe errors (i.e. a SNP was located in the probe leading to spurious 
artifacts). We downloaded these further processed gene expression data from 
(http://eqtnminer.sourceforge.net/). 
Following the successful completion of Phase III of the HapMap project, Stranger and 
colleagues extended their previous study to a more rigorous examination of the influence of 
ancestry on gene expression [15]. In this study, gene expression for lymphoblastoid cell lines 
from 726 individuals in the HapMap III project were measured using Illumina Sentrix Human-6 
Expression BeadChip version 2. The populations measured included CEU, CHG, GIH, JPT, 
LWK, MEX, MKK, and YRI. In the populations overlapping the HapMap II samples, this study 
included a mix of samples from HapMap II and the new individuals added in HapMap III. In 
total, this group measured 47,294 probes, and the data were made freely available at Array 
Express (Series Accession Number E-MTAB-264).  
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Genotypes 
For the 207 individuals from HapMap Phase I and II, genotype data was download from 
release 24 of the International HapMap project. As described in Chapter 2, the third phase of the 
HapMap project did not genotype as many variants as the previous two phases. When comparing 
the SNPs available for the 207 HapMap I and II samples to those available for the 466 Phase III 
HapMap samples, only about ~50% of these had been genotyped. We extract all available 
genotypes from draft release 2 of the International HapMap project for all 466 individuals 
However, 236 of those 466 individuals had also been sequenced as part of the 1000 genomes 
project. Groups have previously performed haplotype phasing (1000G Phase I version 3 MACH 
panels) on those data and have made those data freely available [49,56]. We drew the remaining 
half of the SNPs available in Phase I and II HapMap samples but not Phase III HapMap from this 
resource for the 236 individuals sequenced. 
 
Study Populations 
 
The discovery population consisted of 210 independent multiethnic samples, specifically 
60 CEPH and 60 Yoruba parental samples, 45 Han Chinese and 45 Japanese unrelated 
individuals from the Phase II HapMap Project. Gene expression measures were from Stranger 
et.al. 2007 and genotype data came from release 24 of the International HapMap project. 
The replication set consisted of up to 466 independent multiethnic samples, specifically 
34 Han Chinese, 39 Japanese, 82 Gujarati Indians, 83 Luhya, 134 Maasai, 53 Yoruba and 42 
individuals of Mexican descent in Los Angeles. These were all unrelated individuals from the 
Phase III HapMap Project and although some populations overlapped with our discovery set 
(CHB, JPT & YRI) the individuals tested were independent. Gene expression values were from 
Stranger et. al. 2012, 65 SNPs were draft release 2 of the International HapMap project for all 
466 individuals, and 62 SNPs from 1000G Phase I version 3 MACH panels. Unfortunately, the 
SNPs from the 1000 genomes project only included CHB, JPT, LWK, MXL, and YRI 
individuals giving a total sample size of 236 individuals for those SNPs.  
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A. 
 
B. 
.  
Figure 2. Normal quantile transformation of a single gene across HapMap III samples. 
Lines correspond to the gene expression value for a single individual and gene. Panel A 
shows the original raw gene expression values for each population while Panel B is 
following normal quantile transformation. 
 
Normalization of Gene Expression Values 
 
As part of normal quality control procedures, raw expression levels were normalized with 
quantile normalization within replicates and then median normalized across all samples. These 
quality control methods were performed by Stranger et. al. (2007 and 2012) prior to data 
downloads. However, to be able to combine populations with different distributions of gene 
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expression values, we had to apply additional normalization procedures. We used the normal 
quantile transformation originally proposed by Veyrieras et. al. In this method a single gene’s 
expression value for each individual in a single population is ranked in numerical order. These 
rankings are then transformed by the following equation: 
(     )
 
 
where r is the rank of the gene expression value and n is the number of individuals in the 
population. The value produced by the equation corresponds to the quantile of the standard 
normal distribution that will be assigned as the gene expression value for that gene for that 
individual. Put more simply, this creates a ranking system where the transformed gene 
expression value depends on the relative expression value within the population and the size of 
the population tested. For an example of this transformation in HapMap III only populations, see 
Figure 2  
 
Selection of Single Nucleotide Polymorphisms for Testing 
 
We only chose to investigate SNPs that had a known cis-eQTL effect in lymphoblastoid 
cells lines (as measured in [14]). The original study defined all SNPs within 500kb upstream of 
the transcription start site and 500 kb downstream of the transcription end site as cis-variants. As 
shown in Figure 3, for each of the 744 genes that had at least one significant eQTL (as defined 
by a p-value < 7x10
-6
 which corresponds to a gene-level false discovery rate of 5%) we 
calculated a gene-specific significance threshold using a Bonferroni correction for the number of 
cis-SNPs. Cis-SNPs that met these significance thresholds were further filtered to identify the 
most significant SNP identifying independent loci for each gene. This filtering process relies on 
empirical estimates of linkage disequilibrium as calculated using the clump function in 
PLINK[57]. This algorithm requires four parameters – the significance cutoffs for index and 
clumped SNPs, an LD threshold and a physical distance threshold. We did not set a significance 
threshold for this procedure as all SNPs already met our significance cutoffs. We clumped SNPs 
that were within 250kb of the index SNP that also had an R
2
 of at least 0.5. The most significant 
SNP from each clump was carried forward in the analysis. Any SNP that fell outside of a clump 
were also carried forward for analysis. 
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A. 
 
B. 
 
C. 
 
Figure 3.  SNP Selection Procedure. Panel A illustrates that for all genes tested for cis-eQTL by 
Veyrieras et. al. we only selected those that had at least one eQTL meeting a gene-level false 
discovery rate of 5% (in green). Panel B summarizes the gene specific Bonferroni correction 
based on how many SNPs were tested for each gene independently.  In Gene 2 there were more 
SNPs tested so the significance threshold was proportionally lowered. All SNPs passing this 
threshold (in green) were considered for the analysis. Finally in Panel C, for all significant SNPs 
in Gene 2 a test of linkage disequilibrium removed variants with a correlation higher than 0.5.  In 
cases of LD the most significantly associate SNP was retained (colored green).  SNPs not in LD 
with other variants were also retained (colored green). 
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Pathway-Based trans-eQTL Analysis 
 
Overview of Signaling Pathway Impact Analysis 
Signaling Pathway Impact Analysis calculates two probability measurements. The first is 
analogous to ORA, in that it calculates the probability of observing the number of differentially 
expressed genes in the pathway compared to the null hypothesis of random differential 
expression. This measure will be referred to as PNDE. The second probability measure relates to 
perturbation of the pathway, essentially taking into account which genes in the pathway are 
differentially expressed. This probability is calculated with respect to a perturbation factor 
defined as: 
  (  )    (  )  ∑   
 
   
 
  (  )
   (  )
 
Here E(gi) is the normalized gene expression log fold change. This value is adjusted by the sum 
of the perturbation factor for each of the upstream genes [PF(gj)] after normalization for the 
number of downstream genes [Nds(gj)]. These summed perturbation factors are weighted based 
on the type of interaction with the current gene (e.g. activation, inhibition, etc). This weighting is 
captured using the βij term. Performing this calculation for each differentially expressed gene 
creates a large set of simultaneous equations that can be solved to calculate the perturbation 
factor value for each gene.  
However, to capture the total true pathway perturbation (i.e. the accumulation of effect 
through the pathway) one cannot use the perturbation factor value alone. This is because the 
perturbation factors include the level of gene expression for each gene in the pathway. Instead 
we want to calculated perturbation accumulation – essentially the excess effects on expression 
that is propagated through interconnected differentially expressed genes. This measure is 
caclculated as: 
   (  )    (  )    (  ) 
This measure is then summed across the pathway creating a total accumulated perturbation 
measure. Using bootstrapping, the probability of observing a total accumulation as extreme or 
more extreme by chance alone is calculated and referred to as PPERT. An visual example of these 
effects are presented in Figure 4.  
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Figure 4. Example of SPIA Perturbation Measure.  In this figure two different 
types of pathway dysregulation are compared. Both pathway (a) and (b) would 
have the same PNDE values as they both have two of seven differentially expressed 
genes. However the perturbation statistic, PPERT will be different.  In pathway (a) 
there is a smaller total pathway expression accumulation because the two 
differentially expressed genes (grey) are not directly connected in the pathway. 
Although neither pathway has significant perturbation factors, pathway (b) has a 
smaller statistic because of the cumulative effects of the differentially expressed 
genes, Gene A and Gene B having direct contact in the pathway. Figure from [46]. 
 
Finally, the two measures, (PNDE and PPERT) are combined into a total probability score, 
PG. For each pathway, i, the total probability score is calculated with reference to ci where ci is 
calculated as the product of PNDE and PPERT [e.g.        ( )       ( )]. The calculate for PG is 
as follows: 
           (  ) 
In all cases, the probability measures are independent of pathway size, which allows for direct 
comparison of values among pathways.  
SPIA can be applied to any pathway database that has interconnected nodes connected 
through directed edges. The original implementation of this approach uses human KEGG 
pathways which include a number of cellular and disease pathways. In total there are more than 
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60 human pathways in KEGG, which means that it is necessary to correct probability measures 
calculated in SPIA for multiple testing. Given that these pathways are highly correlated, 
controlling for a 5% false discovery rate (FDR) [58] is appropriate and implemented in the 
original SPIA R package. This measure will be referred to as PGFDR. 
 
Approach 
For each SNP that passed our filtering process, we analyzed the effect of that SNP on 
differential expression of KEGG pathways using the tool Signaling Pathway Impact Analysis 
(SPIA). [46] To determine the effect of each SNP on the various pathways we first regressed 
gene expression values onto the additively encoded genotype for each SNP independently using 
linear regression. Genes with a regression p-value <0.05 were considered differentially 
expressed. Because of the normalization procedures used to combine our populations, we could 
not use the typical log-fold change in gene expression for this analysis. Instead, we used the raw 
beta value from the SNP regression – essentially representing the per-allele additive effect on 
gene expression.  
 
Significance Thresholds 
As mentioned previously, SPIA examines all KEGG pathways an FDR corrected p-value 
(PGFDR) is presented to account for multiple testing at a pathway level. However, because we are 
performing multiple pathway analyses – one for each SNP tested – we need to perform 
additional correction. Each SNP is independent (due to the linkage disequilibrium filtering), so 
we corrected the PGFDR value using a Bonferroni correction for each of the 2909 SNPs tested 
resulting in a threshold of p < 1.7x10
-5
. All SNP-Pathway associations with a PGFDR below this 
threshold were tested for replication in the replication population. Given that we are only testing 
certain SNP-pathway combinations, we will use the unadjusted global p-value (PG) in our 
replication thresholds. We considered SNP-Pathway combinations with nominally significant 
(p<0.05) PG values as replicated. However, to identify SNP-pathway effects that appear to be 
especially robust, we calculated a Bonferroni corrected threshold for the number of SNP-
pathway combinations tested (n=221) a PG threshold of 2.3x10
-4
.  
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Identification of Possible Mechanisms of Action 
 
Investigating Replication of Known cis-eQTL  
Given that we selected SNPs on the basis of their purported cis-eQTL effects found by 
Veyrieras et. al. in our discovery population, we were interested to see if these primary effects 
were able to be replicated. For each of the SNPs with significant SNP-Pathway replication, we 
tested the effect of the SNP on the cis-gene’s expression. Using linear regression, we associated 
additively encoded SNPs on the gene expression value. For SNPs that had multiple cis-eQTL 
genes in our discovery population, we performed regression for the SNP on each gene. Given 
that this is a replication, we used a liberal, nominally significant threshold (p<0.05).  
 
Removing Effect of cis-eQTL Gene Expression 
To determine whether these pathway-based expression changes are propagated through 
the cis-eQTL gene alone or if there are extra trans-effects by these SNPs, we analyzed all SNP-
Pathway combinations that replicated across both datasets. As with the discovery and replication 
analyses, we regressed the gene expression values onto the additively encoded SNP genotype, 
however this time we included the normalized gene expression value of the cis-eQTL gene as a 
covariate. This should give the relative gene expression change that occurs without the effects of 
the expression of this gene. We took the regression results and processed with SPIA as described 
above. For SNPs that act as cis-eQTL for multiple genes, we performed the conditional analysis 
once for each SNP-gene pair. Similar to the replication analysis, we accepted nominally 
significant PGFDR values (<0.05) as significant associations. 
 
Functional Annotation 
Given the nature of this work, we will focus on the transcription related elements from 
ENCODE. These functional elements are identified with the following experimental procedures: 
ChIP-seq of histone proteins and of transcription factors, and DNaseI hypersensitivity assays. 
ChIP procedures cross-link existing DNA-protein complexes (essentially making the interaction 
more solid). The long pieces of DNA crossed-linked to the proteins are broken into smaller 
fragments, and then the fragments of interest are removed for analysis using antibodies to the 
protein of interest. Following unlinking of the DNA-protein complex of interest, either a 
23 
 
microarray chip (ChIP-chip) or sequencing (ChIP-seq) reveal the sequence of the region being 
bound by the protein. When targeting histones this gives valuable information on the chromatin 
state at the region. If transcription factor proteins are targeted, transcription factor binding sites 
(TFBS) are identified. Although the chromatin state implies information on accessible DNA, 
DNaseI hypersensitivity assays actually measure regions of open DNA (implying locations of 
functional elements or active transcription). DNaseI is an enzyme that degrades DNA – in 
regions of accessible DNA, DNaseI will cleave out multiple fragments. Sequencing of these 
fragments and alignment to the reference genome allow for identification of these open DNA 
sites. 
Specifically, in this study we will use chromatin state information (enhancers promoters 
and repressors), regions of open chromatin, and effects of SNPs on regulatory binding motifs 
found in HaploReg [59]. This database uses information from the HapMap project to identify 
whether the SNPs of interest are in linkage disequilibrium with these functional elements. 
Additionally we will examine transcription factor binding sites, and predicted binding locations, 
along with known gene expression regulators (eQTL) found in RegulomeDB [60]. Many of the 
cell lines included in ENCODE and regulation information in these databases are from 
lymphoblastoid cell lines – even in some cases LCLs from the same HapMap samples.  
In summary, for each of the SNPs with replicating SNP-Pathway associations, we 
examined regulatory annotations using HaploReg [59] and RegulomeDB [60]. Specifically we 
annotated each SNP for: 
 Chromatin state information (enhancers promoters and repressors) 
 Regions of open chromatin 
 Effect of SNPs on regulatory binding motifs 
 Transcription factor binding sites (experimentally validated) 
 RegulomeDB Functional Score  
RegulomeDB scores are based on the level of evidence supporting the regulatory function of the 
scored variant. For chromatin states, and effects on regulatory binding motifs we did include 
annotations for variants in strong linkage disequilibrium with our tested SNP. The annotations in 
question have poor resolution and so using nearby SNPs improves the likelihood of identifying 
potential regulatory mechanisms.  
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Annotation of Known SNP and cis-eQTL Gene Effects  
We further examined potential explanations underlying replicating SNP-Pathway 
associations by mapping known associations/functions of both the SNP and its cis-eQTL gene 
using the NCBI catalog. Specifically we annotated SNP effects using dbSNP [61] and genes 
using Entrez Gene [62]. We also investigated whether any of the replicating SNPs had known 
associations from genome-wide association studies. We annotated each SNP using the GWAS 
catalog [1] and the Johnson GWAS Catalog that contains many suggestive associations [63]. 
Finally we completed searches of PubMed for each SNP and gene to investigate prior knowledge 
of SNP and gene function to identify potential explanations for the SNP-pathway association. 
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CHAPTER IV 
 
RESULTS 
 
A total of 853 genes tested in [14] had one or more cis-eQTL SNPs meeting our 
threshold. For these 853 genes, a total of 928,908 SNP-gene pairs were test for cis-eQTL 
activity. After applying a gene-level Bonferroni correction, 22,247 SNP-gene pairs were 
significant. These results contained 21,315 unique SNPs as many SNPs associated with the 
expression of multiple genes. The vast majority (20,482) associated with the expression of a 
single gene. For those associated to multiple genes, 735 associated with two genes, 97 associated 
with three genes, and 1 associated with four genes. Following quality control procedures, 119 
SNPs were removed from analysis as they did not map to the current build of the reference 
genome or were unavailable in the latest version of HapMap genotyping data. For all remaining 
SNPs, we filtered out variants in linkage disequilibrium for each gene set, giving a total of 2909 
SNPs for future analyses. 
 
Discovery and Replication of Pathway-Based trans-eQTL 
 
In the discovery analysis we tested 2,909 SNPs against 137 KEGG pathways.  A total of 
291,257 SNP-pathway combinations had at least one differentially expressed gene in the tested 
pathway. Of these, 240 SNP-Pathway combinations met our Bonferroni-corrected false 
discovery rates and were carried forward for replication. These results represented a total of 135 
SNPs associated with 13 different pathways. Fifty-seven SNPs associated with 2 or more 
pathways. Of these, 23 SNPs associated with 2 pathways, 24 SNPs associated with 3 pathways, 7 
SNPs associated with 4 pathways, 2 SNPs associated with 5 pathways, and 1 SNP associated 
with 6 pathways. A complete listing of these findings can be found in Appendix A.  
Of the 135 SNPs significant in the discovery analysis, 65 were available for all HapMap 
III samples, 65 were available for only a subset of the 1000 Genomes project samples and 5 were 
unavailable for analysis. Those five SNPs accounted for 19 SNP-pathway combinations. Of the 
remaining 221 SNP-pathway combinations, 32 met our nominal significance threshold and 15 
met our Bonferroni corrected global p-value. Result for both the discovery and replication 
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Table 1. Significant Replicating SNP-Pathway Associations 
SNP 
Pathway 
Name 
Discovery Replication 
pSize NDE pNDE tA pPERT pGFdr pSize NDE pNDE tA pPERT pG 
HapMap 3 Samples (n=466) 
rs7586918 
Protein proc. 
in endoplsmc 
reticulum 
105 16 4.56E-09 0.02 0.91 7.66E-06 150 42 3.23E-06 0.57 0.30 1.44E-05 
rs10517012 
Olfactory 
transduction 
67 10 7.40E-04 -7.36 5.00E-06 8.54E-06 361 17 1.00 6.66 5.00E-06 6.60E-05 
rs1162371 
Olfactory 
transduction 
67 28 5.93E-06 9.10 5.00E-06 1.00E-07 361 10 1.00 5.52 5.00E-06 6.60E-05 
rs11104775 
Olfactory 
transduction 
67 36 2.90E-08 11.48 1.00E-03 9.89E-08 361 22 1.00 12.07 5.00E-06 6.60E-05 
rs11104947 
Olfactory 
transduction 
67 25 1.27E-04 10.36 5.00E-06 1.92E-06 361 17 1.00 10.72 5.00E-06 6.60E-05 
1000 Genomes Samples Only (n=236) 
rs6572658 Cell cycle 80 32 8.67E-11 -3.23 0.16 4.78E-08 119 56 7.14E-12 -6.79 0.14 2.84E-11 
rs7681425 
Parkinson's 
disease 
75 29 1.02E-11 0.19 0.83 2.81E-08 105 53 2.41E-09 -4.08 1.50E-02 9.07E-10 
rs7681425 
Huntington's 
disease 
120 33 1.15E-08 0.20 0.89 9.16E-06 163 72 7.09E-09 -0.52 0.56 8.12E-08 
rs11008749 Cell cycle 80 22 9.51E-09 -2.10 0.34 7.95E-06 119 46 2.25E-08 4.43 0.32 1.41E-07 
rs7972875 
Huntington's 
disease 
120 44 4.16E-10 -0.28 0.49 6.32E-07 163 42 3.19E-08 -0.24 0.72 4.27E-07 
rs12475079 
Huntington's 
disease 
120 39 7.02E-09 0.23 0.79 7.23E-06 163 40 3.37E-08 -0.38 0.75 4.64E-07 
rs7867279 
Epstein-Barr 
virus inf. 
128 54 1.40E-07 -1.51 0.10 8.78E-06 177 52 0.03 5.54 5.00E-06 2.58E-06 
rs10131614 RNA trnsprt 84 47 1.60E-11 0.05 0.89 5.07E-08 126 41 4.62E-07 -0.04 0.82 6.01E-06 
rs425437 
Huntington's 
disease 
120 33 8.34E-10 -0.25 0.73 5.91E-07 163 24 2.53E-06 0.00 1.00 3.51E-05 
rs7681425 
Alzheimer's 
disease 
101 29 3.10E-08 0.69 0.37 9.16E-06 148 60 4.04E-06 -0.03 0.99 5.37E-05 
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statistics for the fifteen SNPs passing our Bonferroni correction are presented in Table 1. This 
table contains a few descriptive factors for each association: 
 pSize – the number of genes in the pathway with expression measurements 
 NDE – the number of differentially expressed genes in the pathway 
 pNDE – the probability of observing the number of differentially expressed genes by 
chance alone 
 tA – the total accumulation of expression change through the pathway 
 pPERT – the probability of observing that level of accumulation by chance alone 
 pGFDR – the false discovery rate corrected combined probability of pNDE and pPERT 
 pG – the unadjusted combined probability of pNDE and pPERT 
Additionally the table is broken down by origin of the genotype information as SNPs measured 
by HapMap 3 have nearly double the number of individuals tested as those from the 1000 
Genomes Project. A complete listing of nominally significant replication results can be found in 
Appendix B.  
 
 
Figure 5. Summary of Effect of Cis-eQTL and Cis-Gene on SNP-Pathway Association. For both 
the populations we have three types of data: the cis-eQTL, our SNP-pathway association, and the 
association adjusted for expression level of the cis-gene. Green coloring indicates a statistically 
significant result, while red represents none significant associations. The yellow component 
represents the singular case where the cis-eQTL association for rs7972875 is significant but in 
the opposite direction of effect. From these labels we can group SNPs into different patterns with 
different interpretations on potential effect mechanism.  
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Table 2. Cis-gene Adjusted SNP-Pathway Associations 
Cis-eQTL 
Pathway 
Name 
Population pSize NDE pNDE tA pPERT pG 
Cis-eQTL/Gene Pattern 1 
rs425437 
MOSC2 
Huntington's 
disease 
Discovery 120 56 7.76E-09 -0.03 0.87 1.34E-07 
Replication 163 55 2.44E-04 0.32 0.47 1.15E-03 
rs7586918 
DTNB 
Protein 
processing 
in 
endoplasmic 
reticulum 
Discovery 105 65 7.63E-07 0.60 0.28 3.44E-06 
Replication 150 135 6.88E-13 -0.22 0.78 1.58E-11 
rs7867279 
ZNF510 
Epstein-Barr 
virus inf. 
Discovery 128 92 2.36E-06 -0.17 0.80 2.67E-05 
Replication 177 160 1.83E-13 3.42 0.02 1.31E-13 
Cis-eQTL/Gene Pattern 2 
rs6572658 
L2HGDH 
Cell cycle 
Discovery 80 66 3.02E-06 -1.56 0.29 1.32E-05 
Replication 119 107 2.13E-12 -10.17 0.01 9.60E-13 
rs7681425 
STIM2 
Parkinson's 
disease 
Discovery 75 51 9.32E-07 -0.24 0.73 1.03E-05 
Replication 105 79 1.95E-11 -4.30 9.00E-03 5.32E-12 
Huntington's 
disease 
Discovery 120 70 4.01E-05 -0.10 0.61 2.84E-04 
Replication 163 116 3.07E-13 -0.34 0.71 6.58E-12 
Alzheimer's 
disease 
Discovery 101 58 3.18E-04 0.50 0.33 1.06E-03 
Replication 148 92 2.13E-06 -1.02 0.48 1.50E-05 
rs10131614 
EIF2S1 
RNA 
transport 
Discovery 84 73 3.23E-14 -0.01 0.97 1.00E-12 
Replication 126 121 7.42E-18 -0.11 0.77 2.34E-16 
rs11008749 
ARHGAP12 
Cell cycle 
Discovery 80 68 1.62E-05 -3.06 0.25 5.34E-05 
Replication 119 104 6.05E-10 10.78 6.00E-03 9.93E-11 
rs12475079 
IMMT 
Huntington's 
disease 
Discovery 120 100 2.66E-06 -0.29 0.22 8.88E-06 
Replication 163 133 4.99E-08 -1.02 0.25 2.37E-07 
rs7972875 
VPS33A 
Huntington's 
disease 
Discovery 120 98 2.98E-07 -0.12 0.60 2.94E-06 
Replication 163 134 2.62E-16 -1.04 6.80E-02 7.04E-16 
Cis-eQTL/Gene Pattern 3 
rs1162371 
CEP290 
Olfactory 
transduction 
Discovery 67 43 0.09 2.38 0.23 0.11 
Replication 361 205 1.00 -15.56 5.00E-06 6.60E-05 
rs11104775 
CEP290 
Olfactory 
transduction 
Discovery 67 47 0.36 -1.04 0.63 0.56 
Replication 361 220 1.00 -59.93 5.00E-06 6.60E-05 
rs11104947 
CEP290 
Olfactory 
transduction 
Discovery 67 44 0.37 2.34 0.33 0.38 
Replication 361 209 1.00 -34.49 5.00E-06 6.60E-05 
rs425437 
C1orf115 
Huntington's 
disease 
Discovery 120 48 1.96E-06 -0.01 0.96 2.67E-05 
Replication 163 20 0.26 0.01 0.48 0.39 
Cis-eQTL/Gene Pattern 4 
rs10517012 
TMEM33 
Olfactory 
transduction 
Discovery 67 24 1.00 1.80 0.27 0.62 
Replication 361 205 1.00 24.88 5.00E-06 6.60E-05 
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Figure 6. Cis-eQTL Associations for SNPs with Effect Pattern 1. Genotypes are coded based on 
the number of copies of the minor allele (with respect to the discovery population).  Regression 
lines are presented summarizing direction of effect. Green regression lines indicate associations 
meeting our p-value threshold while red are not statistically significant.  
 
Identification of Potential Mechanisms of Action 
 
For each SNP-Pathway association we identified the cis-eQTL gene for which the SNP 
was originally selected. One SNP, rs425437, was a cis-eQTL for two genes, MOSC2 and 
Clorf115 (open reading frame). Both genes were tested independently in these analyses. 
Following testing of both cis-eQTL effect and adjustment for effect of cis-gene expression on the 
SNP-pathway association, a number of combinations/patterns of effects emerged. A summary of 
the types of patterns observed are presented in Figure 5. In this figure, green boxes represent 
significant associations, while red boxes represent associations that were not statistically 
significant. Importantly, the SNP with two cis-eQTL, rs425437, had divergent patterns based on 
each eQTL gene. Also one SNP, rs7972875, had a significant cis-eQTL in the replication cohort, 
but the opposite direction of effect and was therefore grouped with the other associations that 
lacked cis-eQTL significance in the replication population.  
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Figure 7. Cis-eQTL Associations for SNPs with Effect Pattern 2. Genotypes are coded based on 
the number of copies of the minor allele (with respect to the discovery population).  Regression 
lines are presented summarizing direction of effect. Green regression lines indicate associations 
meeting our p-value threshold while red are not statistically significant. 
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Figure 8. Cis-eQTL Associations for SNPs with Effect Pattern 3. Genotypes are coded based on 
the number of copies of the minor allele (with respect to the discovery population).  Regression 
lines are presented summarizing direction of effect. Green regression lines indicate associations 
meeting our p-value threshold while red are not statistically significant. 
 
The results of the SNP-Pathways associations adjusted for the expression level of the cis-
gene, are presented in Table 2. SNP-gene-pathway combinations are grouped according to the 
effect pattern described in Figure 5. The same statistical measures presented in the unadjusted 
analyses are included in this table. Figures 6-9 are plots of each cis-eQTL in the discovery and 
replication cohorts grouped by their respective effect pattern. Each diagram includes a scatter 
plot of individual expression measurements by genotype, the mean, first and third quantiles for 
expression by genotype (numbers are count of minor allele copies), as well a linear regression 
line. The colors of the line indicate statistical significance based on the gene-specific Bonferroni 
correction in the discovery population and nominal p-value in the replication population.  
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Figure 9. Cis-eQTL Associations for SNPs with Effect Pattern 4. Genotypes are coded based on 
the number of copies of the minor allele (with respect to the discovery population).  Regression 
lines are presented summarizing direction of effect. Green regression lines indicate associations 
meeting our p-value threshold while red are not statistically significant. 
 
Complete results of the functional annotation of variants using HaploReg and 
RegulomeDB are available in Appendix C. We curated these results based on relevance to the 
pathway implicated and the cis-eQTL gene. These filtered results are presented in Table 3 again 
grouped by effect pattern. This table contains a variety of information. DNaseI sensitivity reports 
cell line types for which the SNP is found in open chromatin. Chromatin State includes the 
interpreted chromatin function for the given cell type/s (in parentheses). Transcription Factor 
Binding Sites (TFBS) annotate the transcription factor and the cell line tested while Altered 
Regulatory Motif indicates the relative affinity level of the given transcription factor for the 
minor allele compared to the reference allele. The final data presented is the RegulomeDB score. 
This score is determined based on the level of evidence supporting regulatory function. A score 
of “1f” indicates evidence for an eQTL and either transcription factor binding or a DNase 
hypersensitivity peak. A score of “5” only requires either transcription factor binding or a DNase 
hypersensitivity peak at the variant. Scores of 6 are used as an “other” category that indicates 
minimal binding evidence. Given that these results are only a subset of all the annotations for 
each SNP, there are some types of data available that are not relevant to the SNP-pathway 
association. In these cases the boxes are left blank with no background shading. However, when 
annotation types for variants are not available at all, the entry is shaded with a grey diagonal 
pattern. 
It is important to note that the annotations presented in both Appendix C and Table 3 are 
only for the listed SNP. However, for annotations from HaploReg we did search on all SNPs in 
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Table 3. Relevant SNP Functional Annotations 
SNP / Gene 
Pathway 
DNaseI Sensitivity Chromatin State TFBS Altered Regulatory Motif Regulome
DB Score 
Cis-eQTL/Gene Pattern 1 
rs425437 / MOSC2 
Huntington’s Disease 
 LCL 
 Glioblastoma 
Enhancer (temporal 
lobe, angular gyrus) 
 Increased affinity  for HIF1 1f 
rs7586918 / DTNB 
Protein processing in ER 
 LCL Strong Enhancer 
(LCL) 
  1f 
rs7867279 / ZNF510 
Epstein-Barr virus inf. 
 RPEC   Reduced affinity for NF-1 5 
Cis-eQTL/Gene Pattern 2 
rs6572658 / L2HGDH 
Cell cycle 
   Increased affinity for EVI-1 
and HDAC-2 
No Data 
rs7681425 / STIM2 
Hunt., Park., Alz. Disease 
 Prostate adeno-
carcinoma 
Weak Enhancer 
(adult liver) 
  5 
rs10131614 / EIF2S1 
RNA transport 
   Reduced affinity for Nanog, 
and SOX2 
6 
rs11008749 / ARHGAP12 
Cell cycle 
 Epidermal 
keratinocytes 
  Increased affinity for OCT-1 1f 
rs12475079 / IMMT 
Huntington's disease 
 Choroid plexus 
epithelial cells 
Active enhancer 
(anterior caudate) 
 CTCF (brain, 
muscle) 
Reduced affinity for LUN1s 1f 
rs7972875 / VPS33A 
Huntington's disease 
 LCL   Reduced affinity for NF-1 5 
Cis-eQTL/Gene Pattern 3 
rs1162371 / CEP290 
Olfactory transduction 
 Weak enhancer (cortex)  Reduced affinity for STAT3 6 
rs11104775 / CEP290 
Olfactory transduction 
   Reduced affinity for Dlx2 6 
rs11104947 / CEP290 
Olfactory transduction 
    6 
rs425437 / C1orf115 See entry for rs425437 in Pattern 1.  
Cis-eQTL/Gene Pattern 4 
rs10517012 / TMEM33 
Olfactory transduction 
   Reduced affinity for HNF4 6 
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linkage disequilibrium with our variant (R
2 
> 0.8, European descent population). In only one 
variant did a relevant coding SNP emerge. For rs11104775, cis-eQTL for CEP290 is in moderate 
LD (R
2
 = 0.81, European Descent Population) with rs79705698 a missense variant (Asp→Gly) 
in CEP290. This variant has been deposited into ClinVar – a repository of variants 
used/discovered in clinical genomic testing – by two individuals. Neither group described the 
patient’s phenotype. Only one provided an assessment of pathogenicity and labeled it as a benign 
variant.   
Following annotation for known phenotypic associations using the GWAS Catalog other 
GWAS results, only one SNP had a direct pleiotropic association: rs11104947 (Olfactory 
Transduction). This variant was also associated with vitiligo in a Taiwanese population [64]. 
Two more variants, rs7972875 and rs12475079 were in LD with variants associated with other 
disorders. The first SNP, rs7972875, is in moderate LD R
2
=0.87) with rs11058789 which is 
associated to Type II diabetes [65]. The second SNP, rs12475079, is in high LD (R
2
= 0.96, and 
1.0) with two variants (rs715334 and rs4422155) associated to Parkinson’s disease [66] . It is 
also in high LD (R
2
 = 0.961) to a variant associated with both Rheumatoid Arthritis and 
Parkinson’s disease [65].  
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CHAPTER V 
 
DISCUSSION 
 
This study investigated the hypothesis that a single SNP may affect expression levels of 
distant genes by acting through a biological pathway. To test this hypothesis we performed 
signaling pathway impact analysis of SNPs known to be cis-eQTL on two independent, multi-
ethnic populations. In total we identified 15 highly significant replicating SNP-pathway 
associations.  
 
Interpretation of Possible Mechanisms of Action 
 
Given our requirement that all SNPs needed to be cis-eQTL, it was possible that the 
expression of the cis-eQTL gene could be acting as a confounding variable. In this scenario the 
association between the SNP and pathway may be in fact solely due to effect of the SNP on the 
cis-gene and the cis-gene effect on the pathway. This confounding possibility is shown in Figure 
10. We can test the effect of the potential confounder statistically by adjusting our model for 
expression levels of the cis-gene. Additionally, given that our SNPs were selected as cis-eQTL in 
our discovery population it was possible that some of those cis-effects may not have replicated in 
our second population. This natural experimental condition removes the biological impact of the 
SNP on the gene (and therefore removes the confounding pathway). After testing both scenarios, 
four combinations of these effects were 
identified. Each has its own interpretation 
and as such will be covered individually. 
 
Cis-eQTL/Gene Pattern 1 
In the first pattern, SNP-pathway 
associations in both the discovery and 
replication population were robust to 
expression of the cis-gene when 
controlled for statistically. Visually this is  
 
Figure 10. Example of Association Confounding. 
This figure shows that although a SNP may be 
associated with expression of a pathway (indicated 
by an arrow) it may actually be associating through 
a common factor – the cis-gene.  
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represented in relation to the confounding 
effect in Figure 11. In this group of SNPs, 
the eQTL did replicate so we are unable to 
conclude the impact of removal of the cis-
eQTL on the SNP-pathway association. 
However, given our statistical removal of 
the cis-gene effect we hypothesize that loss 
of the cis-eQTL would not impact the 
association. 
 
Cis-eQTL/Gene Pattern 2 
In the second pattern, SNP-pathway 
associations in both the discovery and replication population were robust to expression of the cis-
gene when controlled for statistically. Additionally, the cis-eQTL did not replicate in the 
replication population. Given that the SNP-pathway association replicated in the unadjusted 
analysis we can conclude that the cis-eQTL effect is not driving for the SNP-pathway 
association. A summary of this result is shown in Figure 12.  
 
Cis-eQTL/Gene Pattern 3 
In the third pattern, the SNP-
pathway association was not robust to 
removal of the cis-gene expression in 
only one population. Figure 13 displays 
this effect. If this were observed in both 
populations there would be stronger 
evidence to suggest that the SNP-
pathway associate is being mediated by 
the expression of the cis-gene. However, 
given that we only see this in a single 
population at a time, a different 
explanation is needed. Unfortunately 
 
Figure 11. Removal of Confounding by 
Statistical Correction. This diagram shows that 
by controlling for expression levels of the cis-
gene, we remove the effect of that gene on the 
pathway and therefore remove the confounding 
effect. If the pathway is still associated we are 
measuring an effect independent of the cis-gene 
(shown as green arrow). 
 
Figure 12. Removal of Confounding by Statistical 
and Biological Correction. This example shows the 
scenario where the SNP no longer is associated 
with the cis-gene (i.e. the eQTL fails to replicate) 
and where the expression of the cis-gene has been 
adjusted for statistically. This indicates a SNP-
pathway association independent of the cis-gene 
(shown as green arrow). 
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without more experimentation it is not clear 
what these results precisely indicate. 
 
 
Cis-eQTL/Gene Pattern 4 
The fourth pattern is the most 
difficult to interpret. For this SNP, the 
eQTL does not replicate in the replication 
population, additionally adjustment for 
expression of the cis-gene does not affect 
the SNP-pathway association (as previously 
shown in Figure 12). However, in the 
discovery population, adjusting for expression of the cis-gene does remove the SNP-pathway 
association (Figure 13). It is hard to reconcile these two results; it is possible that there is some 
other, unmeasured factor/s, that are confounding the association between the SNP and the 
pathway. These factors may be different between our two populations thereby explaining the 
difference in observed effect. 
 
Plausible Biological Interpretations of Functional Annotations 
 
A number of the pathways identified were associated to multiple SNPs. Ignoring 
biological heterogeneity, we assume that similar mechanisms underlie each pathway type. For 
that reason we will discuss the relevant SNP functional annotations and possible mechanisms of 
action for each pathway individually. Unfortunately for one association, Alzheimer’s disease, 
there were no relevant annotations found for the associated SNP (rs7681425). 
 
Cell Cycle Pathway 
Two SNPs, rs6572658 and rs11008749, were associated with the Cell Cycle KEGG 
pathway. While this is a fairly broad phenotype, there were a number of functional elements for 
these SNPs that support this association. First, it was found through DNaseI sensitivity assays 
that the chromatin region around rs11008749 was open in epidermal keratinocytes. This cell type 
 
Figure 13. Example of Confounder Driving 
Association. In this example, when the 
expression of the cis-gene was accounted for 
the statistical model, the SNP-pathway 
association was no longer significant (red X), 
indicating that the cis-gene is somehow 
mediating the association (green arrow). 
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is the outermost layer of the skin and has very unique cell cycle patterns that are not fully 
understood [67]. Although both SNPs have annotations for predicted chromatin state, none were 
particularly compelling for the given pathway. However, both SNPs alter interesting and 
potentially relevant regulatory motifs. The first SNP, rs6572658, is predicted to have increased 
affinity for EVI-1 a known oncogene [68]. This SNP also has increased affinity for HDAC-2 
which, when abnormally regulated, has been shown to deregulate expression important cell cycle 
proteins [69]. Finally, rs11008749 has increased affinity for the OCT-1 transcription factor. 
OCT-1 is required for arresting the cell cycle in the G1 phase of mitosis [70]. 
 
Epstein-Barr Virus Infection Pathway 
Only one SNP, rs7867279 was associated with the Epstein-Barr Virus (EBV) infection 
pathway. Interesting the region surrounding this SNP is in open chromatin in retinal pigment 
epithelial cells (RPEC). This cell type has been shown to not be easily infected by EBV [71]. 
Additionally, this SNP has reduced affinity for nuclear factor 1 (NF-1). In HeLa cells is was 
found that a distal NF-1 consensus site enhanced known promoters responsible for triggering the 
replicative cycle of EBV [72].  It is conceivable that part of the reduced susceptibility of RPEC 
cells to EBV infection may be related to altered function of NF-1 regulatory regions. 
 
Huntington’s Disease Pathway 
This pathway was associated with four different SNPs: rs425437, rs7681425, 
rs12475079, and 7972875. The region surrounding rs425437 and rs7972875 is open chromatin in 
multiple lymphoblastoid cell lines (LCL) from our HapMap population. Additionally rs7586918 
is in a strong enhancer in these cell lines.  Rs425437 is in an enhancer in temporal lobe and 
angular gyrus tissues. Huntington’s patients have been found to have significant loss of neurons 
in the angular gyrus [73,74]. Other chromatin state annotations include rs7681425 in a weak 
enhancer in liver tissue.  Interestingly, mouse models of Huntington’s have been observed to 
have dysfunctional hepatic transcription factors [75].  
The most interesting result, however, is rs12475079.  This SNP is in open chromatin in 
choroid plexus epithelial cells.  In mouse models of Huntington’s disease transplants of choroid 
plexus epithelial cells have been found to protect against neuron damage. Phenotypically the rats 
displayed fewer defects in motor function compared to the control animals [76]. Additionally, in 
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the anterior caudate, rs12475079 is in an active enhancer region. Previous imaging studies have 
identified concentrated deceased in grey matter in the anterior caudate region for individuals 
affected by Huntington’s. The severity of this atrophy was significantly associated with the 
number of CAG repeats each patient inherited [77]. It had been hypothesized that the 
transcription factor CTCF may impact the number of repeats seen in Huntington’s as it is 
associated with many unstable repeat loci.  While this was not found in two fibroblast cultures 
from Huntington’s patients, it is possible that in brain tissue this transcription factor may be 
involved in Huntington’s pathogenesis [78]. This background becomes more interesting in light 
of the fact that rs12475079 is in a CTCF binding site in both brain and muscle tissues.  
 
Olfactory Transduction Pathway 
Olfactory transduction was also associated to four SNPs: rs1162371, rs11104775, 
rs11104947, and rs10517012. The first three of these variants are cis-eQTL for CEP290 – 
centrosome protein 290kDA. This gene plays a crucial role in the function of cilia and is 
associated with numerous ciliopathies [79,80]. Malformations of cilia often impact sensory 
systems, for example, patients with CEP290 mutations causing Leber congenital amaurosis 
exhibited severely abnormal olfactory function [81]. One SNP, rs11104775, is in moderate LD 
with a missense variant in CEP290, though it has not been associated to a particular phenotype. 
While the association may be driven by the missense variant, this SNP also alters a regulatory 
motif for Dlx2 reducing affinity for this transcription factor. Dlx2 is essentially required for 
neurogenesis of all olfactory bulb interneurons [82]. One other interesting altered regulatory 
motif is rs1162371 and STAT3. Phosphorylated STAT3 has been associated with olfactory 
neuroblastomas, but is not typically observed in normal olfactory tissue [83].  
 
Parkinson’s Disease Pathway 
Only one SNP was associated with Parkinson’s disease, rs7681425. While the most 
interesting annotations for this variant are for its association to Huntington’s disease, this SNP is 
in open chromatin regions in prostate carcinoma tissue. This is interesting because in a large 
pedigree study, it was observed that there is a high co-occurrence of prostate cancer and 
Parkinson’s disease. However there has been some indication that this co-occurrence may be due 
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to drug side effects of certain treatments for Parkinson’s symptoms [84].  Our results could 
perhaps provide an alternative explanation. 
 
Protein Processing in the Endoplasmic Reticulum Pathway 
The SNP associated with protein processing in the ER, rs7586918, is in open chromatin 
in HapMap lymphoblastoid cell lines and is in a strong enhancer region.  While there are 
numerous transcription factors that bind this region, it is not clear how these transcription factors 
could be specifically related to this very broad pathway. 
 
RNA Transport Pathway 
One SNP, rs10131614, was associated with RNA transport. While there is not much 
functional data available for this variant, it is predicted to alter regulatory motifs and reduce 
affinity for Nanog and SOX2 transcription factors. Both transcription factors have been shown to 
interact with and regulate long noncoding RNAs in human cells [85,86].   
 
Limitations 
 
Paradoxically, one of this study’s strength is also a significant limitation.  The use of 
multiethnic populations in both the discovery and replication assures for generalizability of 
results, but also reduced our power to detect true associations.  Many associations that are 
population specific would not be identified in this analysis as we used not only multiethnic 
populations, but also we used a different mix of populations in the discovery and replication 
populations.  This reduction in power is only amplified by the required expression normalization 
procedure that allowed us to perform this analysis.  As described in the background, this 
normalization reduces variance in the measured gene expression values. This transformation also 
limits the interpretation of the gene expression values in our analyses as they are not raw 
measurements, but rather standardized values without meaning (for instance it is hard to interpret 
the meaning of a negative gene expression value).   
Another limitation is the use of gene expression measurements from lymphoblastoid cell 
lines.  The cell lines have been immortalized, changing their basic cellular properties in the 
process. While they are widely used is these types of analyses (and results from studies using 
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these cell lines do generalize to tissue), it is important to recognize that these are not 
measurements of a natural environment. The final limitation is the use of the KEGG database.  
While this too is commonly used, due to changes in licensing, this resource has not been updated 
in a number of years. While there is no evidence that the source is inaccurate, if the resource 
were to be updated it likely would contain more (and more detailed) information. 
 
Conclusions and Future Directions 
 
This study identified 32 SNP-Pathway associations that replicated across multiple ethnic 
cohorts. Fifteen of these SNP-Pathway associations were especially robust and were investigated 
more deeply.  In these 15 associations, 4 potential patterns of action with respect to cis-eQTL 
function were identified and interpreted. Finally, functional annotation provided further insight 
into the validity and possible mechanism of action underlying these associations. Future work 
should try to replicate these results in primary tissue samples and investigate potential 
phenotypic associations of the variants identified by this approach. 
 
42 
 
REFERENCES 
 
1. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS 
catalog, a curated resource of snp-trait associations. Nucleic Acids Res 2014, Jan;42(Database 
issue):D1001-6. 
2. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA. 
Potential etiologic and functional implications of genome-wide association loci for human 
diseases and traits. Proceedings of the National Academy of Sciences 2009;106(23):9362-7. 
3. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated snps are 
more likely to be eqtls: Annotation to enhance discovery from GWAS. PLoS Genet 2010, 
Apr;6(4):e1000888. 
4. Gibson G, Weir B. The quantitative genetics of transcription. Trends Genet 2005, 
Nov;21(11):616-23. 
5. Petretto E, Mangion J, Dickens NJ, Cook SA, Kumaran MK, Lu H, et al. Heritability and 
tissue specificity of expression quantitative trait loci. PLoS Genet 2006, Oct 20;2(10):e172. 
6. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, et al. Population genomics 
of human gene expression. Nat Genet 2007, Oct;39(10):1217-24. 
7. Duggal G, Wang H, Kingsford C. Higher-order chromatin domains link eqtls with the 
expression of far-away genes. Nucleic Acids Res 2014, Jan;42(1):87-96. 
8. Phillips J, Eberwine JH. Antisense RNA amplification: A linear amplification method for 
analyzing the mrna population from single living cells. Methods 1996;10(3):283-8. 
9. Lu Q, Richardson B. DNaseI hypersensitivity analysis of chromatin structure. Methods Mol 
Biol 2004;287:77-86. 
10. Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic 
annotation of the human genome. Nat Biotechnol 2010, Aug;28(8):817-25. 
11. Fuda NJ, Ardehali MB, Lis JT. Defining mechanisms that regulate RNA polymerase II 
transcription in vivo. Nature 2009, Sep 10;461(7261):186-92. 
12. Kwan T, Benovoy D, Dias C, Gurd S, Serre D, Zuzan H, et al. Heritability of alternative 
splicing in the human genome. Genome Res 2007, Aug;17(8):1210-8. 
13. Yang S, Liu Y, Jiang N, Chen J, Leach L, Luo Z, Wang M. Genome-wide eqtls and 
heritability for gene expression traits in unrelated individuals. BMC Genomics 2014;15:13. 
43 
 
14. Veyrieras JB, Kudaravalli S, Kim SY, Dermitzakis ET, Gilad Y, Stephens M, Pritchard JK. 
High-resolution mapping of expression-qtls yields insight into human gene regulation. PLoS 
Genet 2008, Oct;4(10):e1000214. 
15. Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, Ingle CE, et al. Patterns of cis 
regulatory variation in diverse human populations. PLoS Genet 2012, Apr;8(4):e1002639. 
16. Michaelson JJ, Loguercio S, Beyer A. Detection and interpretation of expression quantitative 
trait loci (eqtl). Methods 2009, Jul;48(3):265-76. 
17. McKenzie M, Henders AK, Caracella A, Wray NR, Powell JE. Overlap of expression 
quantitative trait loci (eqtl) in human brain and blood. BMC Med Genomics 2014, Jun 3;7(1):31. 
18. Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD, Mirkov S, et al. 
Identification, replication, and functional fine-mapping of expression quantitative trait loci in 
primary human liver tissue. PLoS Genet 2011, May;7(5):e1002078. 
19. Hsiao CL, Lian IeB, Hsieh AR, Fann CS. Modeling expression quantitative trait loci in data 
combining ethnic populations. BMC Bioinformatics 2010;11:111. 
20. Westra H-J, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic 
identification of trans eqtls as putative drivers of known disease associations. Nat Genet 2013, 
Sep;45(10):1238. 
21. Sudarsanam P, Cohen BA. Single nucleotide variants in transcription factors associate more 
tightly with phenotype than with gene expression. PLoS Genet 2014, May;10(5):e1004325. 
22. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide 
association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet 
2011, Nov;43(11):1082-90. 
23. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, et al. A 
statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 
2013, Oct 17;502(7471):377-80. 
24. Breitling R, Li Y, Tesson BM, Fu J, Wu C, Wiltshire T, et al. Genetical genomics: Spotlight 
on QTL hotspots. PLoS Genet 2008, Oct;4(10):e1000232. 
25. Gaffney DJ. Global properties and functional complexity of human gene regulatory variation. 
PLoS Genet 2013, May;9(5):e1003501. 
26. Grundberg E, Small KS, Hedman ÅK, Nica AC, Buil A, Keildson S, et al. Mapping cis- and 
trans-regulatory effects across multiple tissues in twins. Nat Genet 2012, Oct;44(10):1084-9. 
44 
 
27. Fehrmann RS, Jansen RC, Veldink JH, Westra HJ, Arends D, Bonder MJ, et al. Trans-eQTLs 
reveal that independent genetic variants associated with a complex phenotype converge on 
intermediate genes, with a major role for the HLA. PLoS Genet 2011, Aug;7(8):e1002197. 
28. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic 
identification of trans eqtls as putative drivers of known disease associations. Nat Genet 2013, 
Oct;45(10):1238-43. 
29. Williams RW. Expression genetics and the phenotype revolution. Mammalian Genome 
2006;17(6):496-502. 
30. West MA, Kim K, Kliebenstein DJ, van Leeuwen H, Michelmore RW, Doerge RW, St Clair 
DA. Global eqtl mapping reveals the complex genetic architecture of transcript-level variation in 
arabidopsis. Genetics 2007, Mar;175(3):1441-50. 
31. Brynedal B, Raj T, Stranger BE, Bjornson R, Neale BM, Voight BF, Cotsapas C. Cross-
phenotype meta-analysis reveals large-scale trans-eqtls mediating patterns of transcriptional co-
regulation. ArXiv Preprint ArXiv:1402.1728 2014;. 
32. Gilad Y, Rifkin SA, Pritchard JK. Revealing the architecture of gene regulation: The promise 
of eqtl studies. Trends Genet 2008, Aug;24(8):408-15. 
33. Lee E, Bussemaker HJ. Identifying the genetic determinants of transcription factor activity. 
Mol Syst Biol 2010, Sep 21;6:412. 
34. Wu C, Delano DL, Mitro N, Su SV, Janes J, McClurg P, et al. Gene set enrichment in eqtl 
data identifies novel annotations and pathway regulators. PLoS Genet 2008;4(5):e1000070. 
35. Wessel J, Zapala MA, Schork NJ. Accommodating pathway information in expression 
quantitative trait locus analysis. Genomics 2007, Jul;90(1):132-42. 
36. Suthram S, Beyer A, Karp RM, Eldar Y, Ideker T. EQED: An efficient method for 
interpreting eqtl associations using protein networks. Mol Syst Biol 2008, Mar 4;4. 
37. Rashid I, McDermott J, Samudrala R. Inferring molecular interactions pathways from eqtl 
data. Computational Systems Biology 2009, Jan;:211-23. 
38. Tian C, Gregersen PK, Seldin MF. Accounting for ancestry: Population substructure and 
genome-wide association studies. Hum Mol Genet 2008, Oct 15;17(R2):R143-50. 
39. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: 
Tool for the unification of biology. The gene ontology consortium. Nat Genet 2000, 
May;25(1):25-9. 
45 
 
40. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The reactome pathway 
knowledgebase. Nucleic Acids Res 2014, Jan;42(Database issue):D472-7. 
41. Milacic M, Haw R, Rothfels K, Wu G, Croft D, Hermjakob H, et al. Annotating cancer 
variants and anti-cancer therapeutics in reactome. Cancers (Basel) 2012;4(4):1180-211. 
42. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 
2000;28(1):27-30. 
43. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, 
knowledge and principle: Back to metabolism in KEGG. Nucleic Acids Res 2014, 
Jan;42(Database issue):D199-205. 
44. Khatri P, Drăghici S. Ontological analysis of gene expression data: Current tools, limitations, 
and open problems. Bioinformatics 2005;21(18):3587-95. 
45. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene 
set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression 
profiles. Proc Natl Acad Sci U S A 2005, Oct 25;102(43):15545-50. 
46. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim JS, et al. A novel signaling 
pathway impact analysis. Bioinformatics 2009, Jan 1;25(1):75-82. 
47. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001, Mar;27(3):234-6. 
48. Gibbs RA, Belmont JW, Hardenbol P, Willis TD, Yu F, Yang H, et al. The international 
hapmap project. Nature 2003, Dec;426(6968):789. 
49. International HapMap Consortium. A haplotype map of the human genome. Nature 2005, 
Oct 27;437(7063):1299-320. 
50. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second 
generation human haplotype map of over 3.1 million snps. Nature 2007, Oct 18;449(7164):851-
61. 
51. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L, et al. 
Integrating common and rare genetic variation in diverse human populations. Nature 2010, Sep 
2;467(7311):52-8. 
52. Consortium T1GP. A map of human genome variation from population-scale sequencing. 
Nature 2010, Oct;467(7319):1061. 
53. ENCODE Project Consortium. The ENCODE (encyclopedia of DNA elements) project. 
Science 2004, Oct 22;306(5696):636-40. 
46 
 
54. Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, et al. 
Identification and analysis of functional elements in 1% of the human genome by the ENCODE 
pilot project. Nature 2007, Jun 14;447(7146):799-816. 
55. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated 
encyclopedia of DNA elements in the human genome. Nature 2012, Sep 6;489(7414):57-74. 
56. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: Using sequence and genotype data 
to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010, Dec;34(8):816-34. 
57. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: A tool 
set for whole-genome association and population-based linkage analyses. The American Journal 
of Human Genetics 2007;81(3):559-75. 
58. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under 
dependency. Annals of Statistics 2001;:1165-88. 
59. Ward LD, Kellis M. HaploReg: A resource for exploring chromatin states, conservation, and 
regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012, 
Jan;40(Database issue):D930-4. 
60. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of 
functional variation in personal genomes using regulomedb. Genome Res 2012, Sep;22(9):1790-
7. 
61. Sherry ST, Ward M-H, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. DbSNP: 
The NCBI database of genetic variation. Nucleic Acids Res 2001;29(1):308-11. 
62. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez gene: Gene-centered information at 
NCBI. Nucleic Acids Res 2011, Jan;39(Database issue):D52-7. 
63. Johnson AD, O'Donnell CJ. An open access database of genome-wide association results. 
BMC Med Genet 2009;10:6. 
64. Lan CC, Ko YC, Tu HP, Wu CS, Lee CH, Wu CS, Yu HS. Association study between 
keratinocyte-derived growth factor gene polymorphisms and susceptibility to vitiligo vulgaris in 
a taiwanese population: Potential involvement of stem cell factor. Br J Dermatol 2009, 
Jun;160(6):1180-7. 
65. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases 
of seven common diseases and 3,000 shared controls. Nature 2007, Jun 7;447(7145):661-78. 
47 
 
66. Fung HC, Scholz S, Matarin M, Simón-Sánchez J, Hernandez D, Britton A, et al. Genome-
wide genotyping in parkinson's disease and neurologically normal controls: First stage analysis 
and public release of data. Lancet Neurol 2006, Nov;5(11):911-6. 
67. Gandarillas A, Freije A. Cycling up the epidermis: Reconciling 100 years of debate. Exp 
Dermatol 2014, Feb;23(2):87-91. 
68. Buonamici S, Chakraborty S, Senyuk V, Nucifora G. The role of EVI1 in normal and 
leukemic cells. Blood Cells, Molecules, and Diseases 2003;31(2):206-12. 
69. Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ, et al. Aberrant regulation of HDAC2 
mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell 
cycle proteins. PLoS One 2011;6(11):e28103. 
70. Dalvai M, Schubart K, Besson A, Matthias P. Oct1 is required for mtor-induced G1 cell 
cycle arrest via the control of p27(kip1) expression. Cell Cycle 2010, Oct 1;9(19):3933-44. 
71. Huemer HP, Larcher C, Kirchebner W, Klingenschmid J, Göttinger W, Irschick EU. 
Susceptibility of human retinal pigment epithelial cells to different viruses. Graefes Arch Clin 
Exp Ophthalmol 1996, Mar;234(3):177-85. 
72. Glaser G, Vogel M, Wolf H, Niller HH. Regulation of the epstein-barr viral immediate early 
BRLF1 promoter through a distal NF1 site. Arch Virol 1998;143(10):1967-83. 
73. Macdonald V, Halliday GM, Trent RJ, McCusker EA. Significant loss of pyramidal neurons 
in the angular gyrus of patients with huntington's disease. Neuropathol Appl Neurobiol 1997, 
Dec;23(6):492-5. 
74. Ho AK, Nestor PJ, Williams GB, Bradshaw JL, Sahakian BJ, Robbins TW, Barker RA. 
Pseudo-neglect in huntington's disease correlates with decreased angular gyrus density. 
Neuroreport 2004, Apr 29;15(6):1061-4. 
75. Chiang MC, Chern Y, Juo CG. The dysfunction of hepatic transcriptional factors in mice 
with huntington's disease. Biochim Biophys Acta 2011, Sep;1812(9):1111-20. 
76. Borlongan CV, Thanos CG, Skinner SJ, Geaney M, Emerich DF. Transplants of 
encapsulated rat choroid plexus cells exert neuroprotection in a rodent model of huntington's 
disease. Cell Transplantation 2007;16(10):987-92. 
77. Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, et al. Topography 
of cerebral atrophy in early huntingtons disease: A voxel based morphometric MRI study. 
Journal of Neurology, Neurosurgery & Psychiatry 2004;75(2):213-20. 
48 
 
78. Pepers BA, Mastrokolias A, van Ommen G-J, den Dunnen JT, Hoen PB, van Roon-Mom 
WMC. B15 CTCF in huntington's disease. Journal of Neurology, Neurosurgery & Psychiatry 
2012;83(Suppl 1):A10-. 
79. Travaglini L, Brancati F, Attie-Bitach T, Audollent S, Bertini E, Kaplan J, et al. Expanding 
CEP290 mutational spectrum in ciliopathies. Am J Med Genet A 2009, Oct;149A(10):2173-80. 
80. Coppieters F, Lefever S, Leroy BP, De Baere E. CEP290, a gene with many faces: Mutation 
overview and presentation of cep290base. Hum Mutat 2010, Oct;31(10):1097-108. 
81. McEwen DP, Koenekoop RK, Khanna H, Jenkins PM, Lopez I, Swaroop A, Martens JR. 
Hypomorphic CEP290/NPHP6 mutations result in anosmia caused by the selective loss of G 
proteins in cilia of olfactory sensory neurons. Proc Natl Acad Sci U S A 2007, Oct 
2;104(40):15917-22. 
82. Brill MS, Snapyan M, Wohlfrom H, Ninkovic J, Jawerka M, Mastick GS, et al. A dlx2- and 
pax6-dependent transcriptional code for periglomerular neuron specification in the adult 
olfactory bulb. J Neurosci 2008, Jun 18;28(25):6439-52. 
83. Zeng M, Cui Y, Wu C. [Expression of SSTR2 and P-STAT3 in human olfactory 
neuroblastoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2010, Aug;24(15):690-2. 
84. Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared predispositions of 
parkinsonism and cancer: A population-based pedigree-linked study. Arch Neurol 2012, 
Dec;69(12):1572-7. 
85. Sheik Mohamed J, Gaughwin PM, Lim B, Robson P, Lipovich L. Conserved long noncoding 
rnas transcriptionally regulated by oct4 and nanog modulate pluripotency in mouse embryonic 
stem cells. RNA 2010, Feb;16(2):324-37. 
86. Ng SY, Bogu GK, Soh BS, Stanton LW. The long noncoding RNA RMST interacts with 
SOX2 to regulate neurogenesis. Mol Cell 2013, Aug 8;51(3):349-59. 
 
49 
 
APPENDIX A 
 
COMPLETE DISCOVERY ASSOCIATION RESULTS 
 
This table contains all of the significant discovery SNP-Pathway association results. For 
each SNP-pathway combination we report the following measures: 
 pSize – The number of genes in the pathway with gene expression values available 
 NDE – The number of differentially expressed genes in the pathway 
 pNDE – The probability of observing the number of differentially expressed genes by 
chance alone. 
 tA – The total accumulation of effect from differentially expressed genes in the pathway 
 pPERT – The probability of observing the total accumulation value by chance alone 
 pGFDR – The false discovery rate adjusted combined probability of pNDE and pPERT. 
Results are provided in no particular order, though SNPs with associations to multiple pathways 
have their SNP-Pathway statistics grouped together. 
SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs10012092 
Huntington's 
disease 120 59 4.00E-12 -0.93 9.70E-02 1.49E-09 
rs10012092 
Parkinson's 
disease 75 43 4.63E-12 1.63 2.97E-01 2.53E-09 
rs10012092 RNA transport 84 44 1.55E-10 0.87 2.40E-02 4.41E-09 
rs1004579 RNA transport 84 31 4.60E-09 0.29 3.68E-01 4.59E-06 
rs10131614 RNA transport 84 47 1.60E-11 0.05 8.89E-01 5.07E-08 
rs10264186 
Alzheimer's 
disease 101 45 4.13E-16 -1.27 2.66E-01 1.77E-13 
rs10264186 
Huntington's 
disease 120 59 1.89E-23 -0.62 3.15E-01 2.08E-20 
rs10264186 
Parkinson's 
disease 75 46 6.20E-24 1.99 1.56E-01 6.96E-21 
rs10517012 
Olfactory 
transduction 67 10 7.40E-04 -7.36 5.00E-06 8.54E-06 
rs1060435 Cell cycle 80 31 2.33E-09 2.31 1.60E-01 5.25E-07 
rs1060435 
Huntington's 
disease 120 46 5.00E-13 0.42 4.34E-01 8.11E-10 
50 
 
SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs1060435 
Parkinson's 
disease 75 28 3.60E-08 1.44 1.51E-01 4.51E-06 
rs1061338 
Alzheimer's 
disease 101 39 5.35E-11 -0.93 3.20E-01 2.04E-08 
rs1061338 
Huntington's 
disease 120 44 2.42E-11 -0.23 7.20E-01 2.04E-08 
rs1061338 
Parkinson's 
disease 75 37 1.83E-14 0.74 5.74E-01 4.73E-11 
rs10788823 Cell cycle 80 23 2.01E-11 -1.97 3.95E-01 2.72E-08 
rs10794021 Cell cycle 80 21 8.03E-09 2.46 1.22E-01 2.54E-06 
rs10850838 RNA transport 84 39 3.82E-12 -0.57 4.30E-02 6.44E-10 
rs10998219 
Protein 
processing in 
endoplasmic 
reticulum 105 26 1.67E-12 -2.41 6.50E-02 4.06E-10 
rs11008749 Cell cycle 80 22 9.51E-09 -2.10 3.39E-01 7.95E-06 
rs11104775 
Olfactory 
transduction 67 36 2.90E-08 11.48 1.00E-03 9.89E-08 
rs11104947 
Olfactory 
transduction 67 25 1.27E-04 10.36 5.00E-06 1.92E-06 
rs11164929 Cell cycle 80 42 1.92E-11 4.84 2.20E-02 1.64E-09 
rs11164929 RNA transport 84 39 9.96E-09 0.11 8.82E-01 1.13E-05 
rs11230687 
Alzheimer's 
disease 101 28 1.01E-11 -1.25 3.07E-01 3.38E-09 
rs11230687 
Huntington's 
disease 120 35 4.53E-15 -0.40 7.00E-01 6.49E-12 
rs11230687 
Parkinson's 
disease 75 29 2.25E-16 -1.26 4.33E-01 4.39E-13 
rs1162371 
Olfactory 
transduction 67 28 5.93E-06 9.10 5.00E-06 1.00E-07 
rs11704195 
Alzheimer's 
disease 101 32 9.60E-13 2.01 3.71E-01 4.58E-10 
rs11704195 
Huntington's 
disease 120 39 1.15E-15 0.74 5.61E-01 1.51E-12 
rs11704195 
Parkinson's 
disease 75 31 4.46E-16 -1.93 5.19E-01 1.11E-12 
rs1179434 RNA transport 84 36 1.57E-09 -0.02 8.54E-01 3.91E-06 
rs11888 
Parkinson's 
disease 75 25 7.16E-12 0.74 4.08E-01 9.74E-09 
rs1208077 
Huntington's 
disease 120 51 5.47E-09 -0.38 4.88E-01 3.79E-06 
rs1208077 
Parkinson's 
disease 75 40 5.89E-11 -0.32 8.10E-01 1.62E-07 
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SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs12150997 
Huntington's 
disease 120 38 1.67E-08 -0.24 5.54E-01 7.57E-06 
rs12150997 
Parkinson's 
disease 75 33 7.25E-12 -0.74 4.10E-01 1.03E-08 
rs12150997 RNA transport 84 31 5.97E-09 0.25 3.28E-01 2.60E-06 
rs12200420 
Protein 
processing in 
endoplasmic 
reticulum 105 41 5.71E-09 -0.85 5.03E-01 8.07E-06 
rs12238713 
Parkinson's 
disease 75 47 4.00E-09 2.33 3.16E-01 3.72E-06 
rs12274436 RNA transport 84 35 1.06E-08 0.38 5.85E-01 1.66E-05 
rs12475079 
Huntington's 
disease 120 39 7.02E-09 0.23 7.85E-01 7.23E-06 
rs12475079 RNA transport 84 33 4.13E-10 -0.29 2.91E-01 3.76E-07 
rs12511773 Cell cycle 80 45 9.23E-11 -1.97 3.53E-01 3.63E-08 
rs12511773 
Epstein-Barr 
virus infection 128 56 1.04E-07 -2.58 1.80E-02 1.05E-06 
rs12511773 
Huntington's 
disease 120 60 5.55E-11 -0.61 1.93E-01 1.87E-08 
rs12511773 
Protein 
processing in 
endoplasmic 
reticulum 105 52 1.63E-09 -0.89 2.80E-01 3.42E-07 
rs12511773 RNA transport 84 52 1.49E-14 0.62 3.50E-02 2.51E-12 
rs12517057 Cell cycle 80 38 8.15E-14 -5.45 2.70E-02 9.79E-12 
rs12517057 RNA transport 84 35 8.13E-11 0.23 7.79E-01 9.92E-08 
rs12574149 
Protein 
processing in 
endoplasmic 
reticulum 105 26 2.54E-11 -0.53 4.21E-01 3.20E-08 
rs1265163 
Protein 
processing in 
endoplasmic 
reticulum 105 44 1.37E-14 -0.07 9.29E-01 5.66E-11 
rs12800372 
Alzheimer's 
disease 101 43 8.19E-14 -1.46 2.93E-01 5.01E-11 
rs12800372 
Huntington's 
disease 120 41 1.17E-09 -1.03 3.90E-02 4.85E-08 
rs12800372 
Parkinson's 
disease 75 37 1.51E-14 0.10 9.50E-01 5.01E-11 
rs12817892 RNA transport 84 33 4.45E-08 -1.77 5.00E-06 8.92E-10 
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SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs13013390 RNA transport 84 39 1.69E-09 -0.01 9.44E-01 4.54E-06 
rs13191247 
Protein 
processing in 
endoplasmic 
reticulum 105 38 8.26E-14 0.02 9.79E-01 3.25E-10 
rs1378162 Cell cycle 80 31 3.75E-10 2.35 2.86E-01 3.31E-07 
rs1388970 Cell cycle 80 50 1.22E-12 2.91 2.07E-01 4.98E-10 
rs1388970 RNA transport 84 55 4.83E-15 0.70 7.20E-02 1.67E-12 
rs1395259 
Mineral 
absorption 31 6 9.30E-04 -0.34 5.00E-06 1.13E-05 
rs1609798 
Alzheimer's 
disease 101 31 3.16E-09 -1.11 1.57E-01 4.71E-07 
rs1609798 
Huntington's 
disease 120 41 1.70E-13 -0.27 5.61E-01 1.87E-10 
rs1609798 
Parkinson's 
disease 75 33 8.77E-15 0.01 9.90E-01 3.68E-11 
rs1634761 RNA transport 84 36 4.20E-11 -0.03 7.24E-01 1.04E-07 
rs175006 Cell cycle 80 29 4.25E-09 2.49 2.19E-01 2.70E-06 
rs17605444 RNA transport 84 43 5.95E-16 0.02 9.13E-01 2.49E-12 
rs17643917 Cell cycle 80 28 3.46E-10 -2.39 2.44E-01 2.68E-07 
rs1790807 RNA transport 84 44 5.27E-08 0.64 4.00E-02 6.01E-06 
rs1792285 RNA transport 84 32 5.50E-07 -0.98 1.00E-02 1.48E-05 
rs1806294 
Protein 
processing in 
endoplasmic 
reticulum 105 33 1.59E-19 -0.25 7.62E-01 5.52E-16 
rs1878014 
Protein 
processing in 
endoplasmic 
reticulum 105 24 1.64E-08 0.59 2.64E-01 1.01E-05 
rs1885499 
Protein 
processing in 
endoplasmic 
reticulum 105 41 3.64E-08 1.29 9.50E-02 9.57E-06 
rs1903262 
Huntington's 
disease 120 32 1.42E-10 -0.01 9.80E-01 3.79E-07 
rs1903262 
Parkinson's 
disease 75 24 5.02E-10 0.58 5.51E-01 3.79E-07 
rs1947457 Cell cycle 80 36 3.11E-11 3.92 2.35E-01 2.63E-08 
rs2073734 
Alzheimer's 
disease 101 35 5.60E-08 3.10 1.76E-01 8.69E-06 
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SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs2073734 
Huntington's 
disease 120 43 5.21E-10 0.55 8.43E-01 6.73E-07 
rs2073734 
Parkinson's 
disease 75 35 3.54E-12 -1.70 5.90E-01 7.93E-09 
rs2074774 
Dopaminergic 
synapse 78 12 1.38E-03 -1.46 5.00E-06 1.69E-05 
rs210280 Cell cycle 80 16 1.84E-09 -3.00 6.60E-02 2.43E-07 
rs2114647 
Protein 
processing in 
endoplasmic 
reticulum 105 37 1.17E-18 -0.20 8.49E-01 5.54E-15 
rs2184334 
Protein 
processing in 
endoplasmic 
reticulum 105 25 2.61E-09 -0.13 7.81E-01 5.04E-06 
rs2203712 
Parkinson's 
disease 75 21 1.31E-09 0.09 8.01E-01 2.59E-06 
rs2239705 
Alzheimer's 
disease 101 44 4.63E-08 -1.15 3.49E-01 1.37E-05 
rs2239705 
Huntington's 
disease 120 54 3.26E-10 -0.42 4.95E-01 5.02E-07 
rs2239705 
Parkinson's 
disease 75 39 5.19E-10 0.85 6.32E-01 5.02E-07 
rs2290507 
Alzheimer's 
disease 101 39 5.23E-11 1.23 2.32E-01 4.22E-08 
rs2290507 
Parkinson's 
disease 75 32 1.34E-10 -0.02 9.85E-01 2.09E-07 
rs2298581 
Protein 
processing in 
endoplasmic 
reticulum 105 19 1.12E-10 0.44 3.73E-01 1.03E-07 
rs2303115 Cell cycle 80 24 1.62E-09 -2.84 4.50E-02 2.20E-07 
rs2332496 
Huntington's 
disease 120 45 2.95E-08 0.44 1.83E-01 4.83E-06 
rs2332496 
Parkinson's 
disease 75 34 5.50E-09 -0.02 9.68E-01 4.83E-06 
rs2332496 RNA transport 84 39 1.72E-10 -0.70 2.00E-02 1.26E-08 
rs2428521 
Olfactory 
transduction 67 27 6.46E-04 -9.60 5.00E-06 9.09E-06 
rs243324 Cell cycle 80 38 9.00E-11 -2.15 1.79E-01 2.69E-08 
rs243324 
Fanconi 
anemia 
pathway 25 17 1.29E-08 0.23 2.55E-01 1.74E-06 
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SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs243324 
Huntington's 
disease 120 54 1.64E-13 -0.23 4.70E-01 3.10E-10 
rs243324 
Parkinson's 
disease 75 37 3.91E-11 0.30 6.83E-01 2.91E-08 
rs243324 RNA transport 84 38 5.37E-10 0.35 9.30E-02 3.98E-08 
rs252646 Cell cycle 80 21 8.10E-12 -3.87 3.30E-02 9.77E-10 
rs2526478 Cell cycle 80 30 1.75E-09 -2.21 1.43E-01 3.62E-07 
rs2526478 
Huntington's 
disease 120 38 3.44E-09 -0.24 4.51E-01 1.37E-06 
rs2526478 RNA transport 84 33 6.29E-11 0.10 9.53E-01 1.84E-07 
rs266805 
Huntington's 
disease 120 57 9.95E-12 -0.21 5.50E-01 2.00E-08 
rs266805 RNA transport 84 42 7.22E-10 0.51 7.10E-02 8.60E-08 
rs2668427 
Epstein-Barr 
virus infection 128 75 1.08E-08 0.72 6.07E-01 5.95E-06 
rs2668427 
Huntington's 
disease 120 76 5.02E-11 -0.48 4.02E-01 3.54E-08 
rs2668427 
Parkinson's 
disease 75 49 3.13E-08 1.50 2.97E-01 6.21E-06 
rs2668427 RNA transport 84 67 9.30E-18 0.74 8.00E-03 4.59E-16 
rs2688590 RNA transport 84 49 1.03E-15 -0.11 7.94E-01 3.86E-12 
rs2695317 
Protein 
processing in 
endoplasmic 
reticulum 105 34 2.41E-18 0.19 8.09E-01 1.08E-14 
rs2746029 
Huntington's 
disease 120 30 3.51E-12 0.20 8.04E-01 9.18E-09 
rs2746029 
Parkinson's 
disease 75 21 6.65E-10 -0.67 4.01E-01 3.63E-07 
rs277384 
Protein 
processing in 
endoplasmic 
reticulum 105 39 8.18E-11 -0.27 7.11E-01 1.77E-07 
rs277384 RNA transport 84 30 3.52E-08 0.27 3.55E-01 1.49E-05 
rs2915228 
Viral 
myocarditis 35 5 1.08E-03 -0.92 5.00E-06 1.17E-05 
rs2967359 
Alzheimer's 
disease 101 39 2.56E-09 -0.92 2.04E-01 5.22E-07 
rs2967359 
Huntington's 
disease 120 45 4.74E-10 -0.33 4.10E-01 4.73E-07 
rs2967359 
Parkinson's 
disease 75 33 8.26E-10 -0.80 3.73E-01 4.73E-07 
55 
 
SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs3095250 
Alzheimer's 
disease 101 43 5.82E-14 -0.68 4.66E-01 3.82E-11 
rs3095250 
Huntington's 
disease 120 50 1.48E-15 -0.46 2.19E-01 7.78E-13 
rs3095250 
Parkinson's 
disease 75 42 3.58E-19 1.22 3.40E-01 7.11E-16 
rs329312 
Protein 
processing in 
endoplasmic 
reticulum 105 19 3.21E-09 -0.13 7.92E-01 4.60E-06 
rs3747956 Cell cycle 80 23 3.90E-09 -2.20 1.00E-01 1.06E-06 
rs3750131 RNA transport 84 47 6.02E-10 0.04 8.73E-01 1.57E-06 
rs3750132 RNA transport 84 42 3.72E-09 0.14 6.05E-01 6.31E-06 
rs3823943 
Huntington's 
disease 120 38 5.05E-10 0.21 5.73E-01 4.45E-07 
rs3823943 
Parkinson's 
disease 75 29 2.86E-10 -0.05 9.36E-01 4.45E-07 
rs3910384 
Parkinson's 
disease 75 26 2.18E-09 -0.40 7.42E-01 4.39E-06 
rs4144887 Cell cycle 80 38 1.84E-12 -5.87 7.00E-03 2.86E-11 
rs4144887 RNA transport 84 40 4.31E-13 0.75 1.60E-02 2.86E-11 
rs425437 
Alzheimer's 
disease 101 29 2.97E-09 -1.06 2.00E-01 5.91E-07 
rs425437 
Huntington's 
disease 120 33 8.34E-10 -0.25 7.25E-01 5.91E-07 
rs425437 
Parkinson's 
disease 75 27 3.37E-11 -1.38 2.23E-01 2.64E-08 
rs4281907 RNA transport 84 42 4.73E-09 -0.29 2.42E-01 3.28E-06 
rs4346637 
Alzheimer's 
disease 101 44 1.35E-13 -1.00 2.22E-01 4.27E-11 
rs4346637 
Huntington's 
disease 120 56 1.22E-18 -0.52 2.28E-01 1.62E-15 
rs4346637 
Parkinson's 
disease 75 41 4.04E-17 -1.78 9.70E-02 1.07E-14 
rs4346637 RNA transport 84 30 2.43E-07 0.76 7.00E-03 1.20E-06 
rs4489748 Cell cycle 80 28 1.59E-11 0.33 8.88E-01 4.54E-08 
rs4626725 Cell cycle 80 58 3.06E-10 -2.81 3.68E-01 1.84E-07 
rs4626725 RNA transport 84 61 9.46E-11 0.89 1.90E-02 6.91E-09 
rs4674297 
Alzheimer's 
disease 101 48 7.33E-09 2.30 5.10E-02 2.82E-07 
rs4674297 
Huntington's 
disease 120 61 1.79E-12 0.43 3.24E-01 1.12E-09 
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SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs4674297 
Parkinson's 
disease 75 44 3.91E-12 0.36 7.75E-01 3.70E-09 
rs4674297 RNA transport 84 53 3.00E-16 -0.86 1.20E-02 1.97E-14 
rs4750935 
Alzheimer's 
disease 101 46 1.79E-11 -2.30 1.03E-01 2.29E-09 
rs4750935 
Huntington's 
disease 120 60 6.19E-17 -0.40 5.97E-01 9.55E-14 
rs4750935 
Parkinson's 
disease 75 46 6.80E-18 0.90 6.24E-01 2.31E-14 
rs4750935 RNA transport 84 34 2.70E-07 1.37 4.00E-03 7.77E-07 
rs4899667 RNA transport 84 27 3.60E-09 -0.02 9.61E-01 9.14E-06 
rs5743030 Cell cycle 80 31 5.75E-13 1.53 5.71E-01 1.22E-09 
rs6073555 
Alzheimer's 
disease 101 41 1.95E-08 -1.01 4.03E-01 6.83E-06 
rs6073555 
Huntington's 
disease 120 47 7.16E-09 0.06 8.96E-01 6.83E-06 
rs6073555 
Parkinson's 
disease 75 39 4.87E-12 -0.55 7.68E-01 1.36E-08 
rs6075348 RNA transport 84 38 6.74E-15 -0.50 4.00E-02 1.27E-12 
rs6469265 RNA transport 84 28 2.46E-08 -0.46 2.70E-01 1.63E-05 
rs6572658 Cell cycle 80 32 8.67E-11 -3.23 1.63E-01 4.78E-08 
rs6683015 
Protein 
processing in 
endoplasmic 
reticulum 105 21 2.26E-09 0.03 9.27E-01 5.59E-06 
rs6687042 Cell cycle 80 27 3.36E-08 -4.66 7.10E-02 3.11E-06 
rs6687042 RNA transport 84 30 1.25E-09 0.28 7.08E-01 2.41E-06 
rs675679 
Huntington's 
disease 120 50 2.56E-08 1.10 1.38E-01 9.85E-06 
rs6964421 Melanogenesis 67 7 6.76E-04 -6.16 5.00E-06 6.24E-06 
rs6967487 
Protein 
processing in 
endoplasmic 
reticulum 105 37 2.79E-09 0.08 9.30E-01 7.12E-06 
rs7014589 Cell cycle 80 28 1.87E-11 -2.56 4.19E-01 2.64E-08 
rs7015262 Cell cycle 80 21 1.50E-10 -1.32 4.19E-01 1.71E-07 
rs7093644 
Huntington's 
disease 120 61 1.36E-09 0.59 2.08E-01 8.84E-07 
rs7116631 
Alzheimer's 
disease 101 48 2.56E-09 0.65 5.14E-01 9.26E-07 
rs7116631 Cell cycle 80 41 2.21E-09 2.79 1.85E-01 4.04E-07 
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SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs7116631 
Huntington's 
disease 120 55 9.78E-10 0.59 2.50E-01 3.71E-07 
rs7116631 
Parkinson's 
disease 75 39 3.16E-09 0.00 9.96E-01 1.70E-06 
rs7116631 
Protein 
processing in 
endoplasmic 
reticulum 105 48 1.26E-08 0.56 5.30E-01 2.88E-06 
rs7116631 RNA transport 84 44 2.28E-10 -0.39 1.91E-01 1.42E-07 
rs7209818 
Alzheimer's 
disease 101 31 9.03E-09 -1.28 2.25E-01 2.71E-06 
rs7209818 
Parkinson's 
disease 75 29 5.49E-11 -1.55 3.20E-01 5.75E-08 
rs725229 Cell cycle 80 60 1.19E-12 -2.57 5.27E-01 1.25E-09 
rs725229 RNA transport 84 65 9.82E-15 0.70 1.62E-01 7.64E-12 
rs7260668 
Huntington's 
disease 120 41 1.78E-09 -0.05 6.91E-01 1.70E-06 
rs7260668 
Parkinson's 
disease 75 35 9.64E-13 0.67 5.75E-01 2.09E-09 
rs7351086 
Protein 
processing in 
endoplasmic 
reticulum 105 23 1.50E-16 0.07 8.64E-01 3.99E-13 
rs735738 RNA transport 84 34 2.71E-13 -0.45 1.04E-01 1.19E-10 
rs7422930 RNA transport 84 51 7.01E-18 -0.30 3.42E-01 1.33E-14 
rs752239 Cell cycle 80 36 3.34E-08 1.81 3.79E-01 1.63E-05 
rs752239 RNA transport 84 41 1.71E-10 -0.42 1.19E-01 6.99E-08 
rs7539844 
Alzheimer's 
disease 101 23 1.12E-08 -1.39 1.81E-01 1.56E-06 
rs7539844 
Huntington's 
disease 120 31 8.69E-13 -0.40 7.31E-01 2.01E-09 
rs7539844 
Parkinson's 
disease 75 24 2.22E-12 -0.90 5.81E-01 2.01E-09 
rs7586918 
Protein 
processing in 
endoplasmic 
reticulum 105 16 4.56E-09 0.02 9.09E-01 7.66E-06 
rs7616874 
Protein 
processing in 
endoplasmic 
reticulum 105 28 7.43E-11 0.21 7.28E-01 1.65E-07 
rs7621332 
Huntington's 
disease 120 49 1.46E-09 2.34 3.69E-01 7.83E-07 
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SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs7621332 
Parkinson's 
disease 75 34 2.11E-08 0.00 9.99E-01 1.71E-05 
rs7621332 RNA transport 84 40 1.91E-10 -0.64 5.04E-01 3.01E-07 
rs7632176 RNA transport 84 53 3.75E-17 -0.30 3.45E-01 7.07E-14 
rs7651414 
Protein 
processing in 
endoplasmic 
reticulum 105 29 5.24E-13 0.39 5.45E-01 8.79E-10 
rs765256 
Alzheimer's 
disease 101 33 2.04E-09 0.59 4.23E-01 1.18E-06 
rs765256 
Huntington's 
disease 120 36 5.19E-09 0.20 7.57E-01 3.33E-06 
rs765256 
Parkinson's 
disease 75 29 2.09E-10 -1.06 2.82E-01 1.81E-07 
rs7675985 Cell cycle 80 44 1.02E-09 -0.57 7.76E-01 1.18E-06 
rs7675985 RNA transport 84 56 3.72E-17 0.30 3.99E-01 8.03E-14 
rs7681425 
Alzheimer's 
disease 101 29 3.10E-08 0.69 3.68E-01 9.16E-06 
rs7681425 
Huntington's 
disease 120 33 1.15E-08 0.20 8.91E-01 9.16E-06 
rs7681425 
Parkinson's 
disease 75 29 1.02E-11 0.19 8.29E-01 2.81E-08 
rs7739002 
Alzheimer's 
disease 101 32 1.14E-09 0.70 6.26E-01 1.04E-06 
rs7739002 
Parkinson's 
disease 75 29 2.95E-11 1.07 5.60E-01 5.63E-08 
rs7780322 RNA transport 84 32 4.17E-09 -0.66 9.50E-02 1.15E-06 
rs7794040 RNA transport 84 27 5.59E-09 -0.29 6.03E-01 9.06E-06 
rs7844633 
Alzheimer's 
disease 101 26 1.67E-10 0.58 3.42E-01 1.62E-07 
rs7844633 
Parkinson's 
disease 75 21 1.84E-09 0.80 3.40E-01 7.98E-07 
rs7867279 
Alzheimer's 
disease 101 46 7.57E-08 -1.07 1.75E-01 8.78E-06 
rs7867279 
Epstein-Barr 
virus infection 128 54 1.40E-07 -1.51 9.60E-02 8.78E-06 
rs7867279 
Huntington's 
disease 120 62 4.49E-13 -0.51 2.26E-01 4.30E-10 
rs7867279 
Parkinson's 
disease 75 42 9.47E-11 -0.41 6.92E-01 1.10E-07 
rs7972875 
Huntington's 
disease 120 44 4.16E-10 -0.28 4.90E-01 6.32E-07 
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SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs8077875 
Parkinson's 
disease 75 27 9.01E-10 2.05 4.48E-01 1.22E-06 
rs8107491 
Alzheimer's 
disease 101 24 5.96E-10 -1.36 3.60E-02 3.43E-08 
rs8107491 
Huntington's 
disease 120 26 9.90E-10 0.00 1.00E+00 8.96E-07 
rs8107491 
Parkinson's 
disease 75 25 6.32E-14 -0.85 3.80E-01 9.71E-11 
rs8436 
Alzheimer's 
disease 101 54 2.77E-10 -1.59 1.02E-01 2.43E-08 
rs8436 
Huntington's 
disease 120 69 7.33E-15 -0.39 3.61E-01 4.14E-12 
rs8436 
Parkinson's 
disease 75 53 3.10E-17 1.18 2.55E-01 4.34E-14 
rs8436 RNA transport 84 55 1.56E-15 0.61 2.40E-02 9.85E-14 
rs9263966 
Huntington's 
disease 120 37 1.11E-10 -0.36 8.14E-01 2.88E-07 
rs9263966 
Parkinson's 
disease 75 27 7.93E-10 1.27 4.60E-01 5.47E-07 
rs9299013 
Huntington's 
disease 120 51 1.09E-08 -0.82 4.70E-02 1.57E-06 
rs9374118 
Protein 
processing in 
endoplasmic 
reticulum 105 25 6.97E-09 0.42 5.21E-01 9.20E-06 
rs9398120 
Alzheimer's 
disease 101 36 6.37E-08 -1.32 1.68E-01 6.78E-06 
rs9398120 
Huntington's 
disease 120 51 4.28E-14 -0.33 4.60E-01 4.19E-11 
rs9398120 
Parkinson's 
disease 75 43 4.23E-18 0.94 4.98E-01 1.15E-14 
rs9398120 RNA transport 84 32 5.66E-08 0.61 4.50E-02 2.31E-06 
rs9601213 
Alzheimer's 
disease 101 28 1.31E-14 -0.37 5.52E-01 2.25E-11 
rs9601213 
Huntington's 
disease 120 26 5.46E-11 -0.19 8.67E-01 3.64E-08 
rs9601213 
Parkinson's 
disease 75 24 3.05E-14 -0.22 7.49E-01 3.44E-11 
rs986475 
Alzheimer's 
disease 101 37 2.04E-10 -1.47 2.13E-01 4.57E-08 
rs986475 
Huntington's 
disease 120 48 8.05E-15 -0.47 4.41E-01 7.73E-12 
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SNP 
Pathway 
Name pSize NDE pNDE tA pPERT pGFdr 
rs986475 
Parkinson's 
disease 75 39 5.45E-17 0.33 8.83E-01 2.36E-13 
rs9896436 Cell cycle 80 24 4.16E-09 2.26 1.09E-01 1.21E-06 
rs9901660 
Huntington's 
disease 120 27 2.86E-08 -0.75 2.00E-02 6.87E-07 
rs9901660 
Parkinson's 
disease 75 23 4.92E-10 -1.06 4.43E-01 5.47E-07 
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APPENDIX B 
 
COMPLETE REPLICATION ASSOCIATION RESULTS 
 
This table contains all of the significant replication SNP-Pathway association results. For 
each SNP-pathway combination we report the following measures: 
 pSize – The number of genes in the pathway with gene expression values available 
 NDE – The number of differentially expressed genes in the pathway 
 pNDE – The probability of observing the number of differentially expressed genes by 
chance alone. 
 tA – The total accumulation of effect from differentially expressed genes in the pathway 
 pPERT – The probability of observing the total accumulation value by chance alone 
 pG – The combined probability of pNDE and pPERT. 
Results are provided in order of increasing global p-value. SNPs with multiple pathway 
associations are not grouped together. 
SNP Pathway Name pSize NDE pNDE tA pPERT pG 
rs6572658 Cell cycle 119 56 7.14E-12 -6.79 0.14 2.84E-11 
rs7681425 
Parkinson's 
disease 
105 53 2.41E-09 -4.08 0.02 9.07E-10 
rs7681425 
Huntington's 
disease 
163 72 7.09E-09 -0.52 0.56 8.12E-08 
rs11008749 Cell cycle 119 46 2.25E-08 4.43 0.32 1.41E-07 
rs7972875 
Huntington's 
disease 
163 42 3.19E-08 -0.24 0.72 4.27E-07 
rs12475079 
Huntington's 
disease 
163 40 3.37E-08 -0.38 0.75 4.64E-07 
rs7867279 
Epstein-Barr 
virus infection 
177 52 0.03 5.54 5.00E-06 2.58E-06 
rs10131614 RNA transport 126 41 4.62E-07 -0.04 0.82 6.01E-06 
rs7586918 
Protein 
processing in 
endoplasmic 
reticulum 
150 42 3.23E-06 0.57 0.30 1.44E-05 
rs425437 
Huntington's 
disease 
163 24 2.53E-06 0.00 1.00 3.51E-05 
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SNP Pathway Name pSize NDE pNDE tA pPERT pG 
rs7681425 
Alzheimer's 
disease 
148 60 4.04E-06 -0.03 0.99 5.37E-05 
rs10517012 
Olfactory 
transduction 
361 17 1.00 6.66 5.00E-06 6.60E-05 
rs1162371 
Olfactory 
transduction 
361 10 1.00 5.52 5.00E-06 6.60E-05 
rs11104775 
Olfactory 
transduction 
361 22 1.00 12.07 5.00E-06 6.60E-05 
rs11104947 
Olfactory 
transduction 
361 17 1.00 10.72 5.00E-06 6.60E-05 
rs2688590 RNA transport 126 38 4.39E-05 -0.37 0.48 2.48E-04 
rs6967487 
Protein 
processing in 
endoplasmic 
reticulum 
150 27 1.54E-04 0.36 0.53 8.48E-04 
rs8436 
Alzheimer's 
disease 
148 18 1.52E-03 1.64 0.06 9.41E-04 
rs735738 RNA transport 126 34 9.41E-04 -0.32 0.16 1.46E-03 
rs6687042 Cell cycle 119 23 1.66E-03 4.52 0.17 2.63E-03 
rs425437 
Parkinson's 
disease 
105 14 8.46E-04 0.00 1.00 6.83E-03 
rs7780322 RNA transport 126 18 1.14E-03 0.00 1.00 8.87E-03 
rs2526478 Cell cycle 119 25 0.57 3.21 3.00E-03 0.01 
rs3750131 RNA transport 126 29 4.40E-03 -0.16 0.52 0.02 
rs6687042 RNA transport 126 22 7.39E-03 -0.44 0.36 0.02 
rs425437 
Alzheimer's 
disease 
148 16 3.51E-03 0.08 0.88 0.02 
rs1388970 Cell cycle 119 8 4.33E-01 1.58 0.01 0.03 
rs4626725 RNA transport 126 23 6.46E-03 -0.43 0.77 0.03 
rs1634761 RNA transport 126 33 0.01 -0.10 0.49 0.03 
rs4626725 Cell cycle 119 21 0.01 2.36 0.46 0.04 
rs329312 
Protein 
processing in 
endoplasmic 
reticulum 
150 18 0.29 -0.87 0.03 0.04 
rs8436 
Huntington's 
disease 
163 16 0.02 -0.33 0.42 0.05 
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APPENDIX C 
 
COMPLETE FUNCTIONAL ANNOTATION RESULTS 
 
This table contains all of the functional annotation results for each of the SNP-Gene-
Pathway associations. This table contains a variety of information: 
 DNaseI sensitivity: Cell line types for which the SNP is found in open chromatin.  
 Chromatin State: Interpreted chromatin function for the given cell type/s. 
 Transcription Factor Binding Sites (TFBS): The transcription factor and the cell line 
tested. 
 Altered Regulatory Motif: The relative affinity level of the given transcription factor for 
the minor allele compared to the reference allele.  
 RegulomeDB score:  Level of evidence supporting regulatory function.  
o 1f: evidence for an eQTL and either transcription factor binding or a DNase 
hypersensitivity peak.  
o 5: Either transcription factor binding or a DNase hypersensitivity peak at the 
variant.  
o 6: “Other” category indicating minimal binding evidence 
When an annotation type is not available, the entry is shaded with a grey diagonal pattern. 
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SNP / Gene 
Pathway 
DNaseI Sensitivity Chromatin State TFBS Altered Regulatory 
Motif 
Regulome
DB Score 
rs425437 / MOSC2, 
C1orf115 
Huntington’s Disease 
 LCL 
 Glioblastoma 
 Prostate 
adenocarcinoma 
 Primary tracheal 
epithelial cells 
 Enhancer  
― Brain Inferior Temporal 
Lobe 
― Brain Angular Gyrus 
 Weak Enhancer 
― H1 Derived 
Mesenchymal Stem Cells 
― Pancreas 
― Spleen 
 Transcription Enhancer-like 
―  Gastric 
 Transcription Enhancer-like 
(short gene) 
―  H1 BMP4 Derived 
Trophoblast Cultured 
Cells 
  Increased 
affinity: 
― HIF1 
1f 
rs7586918 / DTNB 
Protein processing in 
ER 
 LCL 
 Primary Th1 and Th2 
T cells 
 Chronic lymphocytic 
leukemia 
 Medulloblastoma 
 Osteoblasts 
 Urothelial cells 
 CD4+ cells 
 B cells 
 hematopoietic 
progenitor cells 
 Strong Enhancer 
― LCL 
 Active Enhancer  
― Mobilized CD34 Primary 
Cells 
 Enhancer 
― Spleen 
 Weak Enhancer 
―  Mobilized CD34 
Primary Cells 
― CD34 Primary Cells 
― CD3 Primary Cells 
― CD8 Naïve & Memory 
Primary Cells 
― CD19 Primary Cells 
 LCL 
― PBX3 
― POL2 
― POL24H8 
― PU1 
― SIN3AK20 
― SRF 
― TBP 
― TCF12 
 
1f 
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SNP / Gene 
Pathway 
DNaseI Sensitivity Chromatin State TFBS Altered Regulatory 
Motif 
Regulome
DB Score 
rs7867279 / ZNF510 
Epstein-Barr virus 
inf. 
 Retinal pigment 
epithelial cells 
 Fibroblasts, 
Hutchinson-Gilford 
progeria syndrome 
 Weak Enhancer 
― Fetal Heart 
 
  Reduced affinity: 
― NF-1 
5 
rs6572658 / 
L2HGDH 
Cell cycle 
  Weak Enhancer 
― Fetal Heart 
  Reduced affinity: 
― Evi-1_2 
― HDAC2_disc6 
No Data 
rs7681425 / STIM2 
Hunt., Park., Alz. 
Disease 
 Prostate adeno-
carcinoma 
 Weak Enhancer 
― Adult Liver 
  
5 
rs10131614 / EIF2S1 
RNA transport 
    Reduced affinity: 
― COMP1 
― FAC1 
― Foxa 
― Foxd3 
― Foxk1 
― Foxo_2 
― Foxp1 
― Nanog 
― Sin3AK-
20_disc3 
― Sox_13 
― Sox_2 
― Sox_6 
― ZFP105 
― P300_disc5 
 Increased 
affinity: 
― HMG-IY_2 
― RREB-1_2 
6 
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SNP / Gene 
Pathway 
DNaseI Sensitivity Chromatin State TFBS Altered Regulatory 
Motif 
Regulome
DB Score 
rs11008749 / 
ARHGAP12 
Cell cycle 
 Epidermal 
keratinocytes 
 Active Enhancer 
― CD4+ CD25- IL17+ 
PMA-Ionomcyin 
stimulated Th17 Primary 
Cells  
 Weak Enhancer 
― CD4+ CD25- CD45RA+ 
Naive Primary Cells 
― CD8 Naive Primary Cells 
― CD4 Memory Primary 
Cells 
 Transcription Enhancer-like 
―  CD4+ CD25- Th 
Primary Cells 
― CD4+ CD25- IL17- 
PMA-Ionomycin 
stimulated MACS 
purified Th Primary Cells 
― CD4+ CD25- CD45RO+ 
Memory Primary Cells 
― Mesenchymal Stem Cell 
Derived Adipocyte 
Cultured Cells 
― CD15 Primary Cells 
― CD4 Naive Primary Cells 
― Colon Smooth Muscle 
― Penis Foreskin 
Melanocyte 
― CD8 Memory Primary 
Cells 
― CD3 Primary Cells 
 
 
 
  Increased 
affinity: 
― OCT-1 
― ZFP187 
1f 
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SNP / Gene 
Pathway 
DNaseI Sensitivity Chromatin State TFBS Altered Regulatory 
Motif 
Regulome
DB Score 
rs12475079 / IMMT 
Huntington's disease 
 Choroid plexus 
epithelial cells 
 LCL 
 epithelial cell line 
from lung carcinoma  
 embryonic stem cells 
 hepatocellular carc. 
 leukemia 
 mammary gland, 
adenocarcinoma 
 epid. keratinocytes 
 fetal buttock/thigh 
fibroblast 
 gingival fibroblasts 
 promyelocytic 
leukemia cells 
 blood microvascular 
endothelial cells, lung 
 neonatal blood 
microvascular 
endothelial cells, 
dermal 
 renal cortical 
epithelial cells 
 T lymphoblastoid  
 acute promyelocytic 
leukemia 
 malignant pluripotent 
embryonal carcinoma 
 renal proximal tubule 
epithelial cells 
 primary Th2 T cells 
 Active Promoter 
― HepG2  
 Weak Promoter 
― LCL; NHLF; HMEC; 
Huvec; NHEK; HSMM; 
H1  
 Strong Enhancer 
― K562  
 Active Enhancer 
― CC.TPC; R.MUC31; 
CCCRA.NP; 
CCC.TREGP; 
CCIP.LSTP; 
CD34.MBP1536; 
LNG.FE; BN.FE2; 
BN.AC; SPL; ST.MUC; 
CD19.P; CCCRO.MP 
 Enhancer 
― ESO; CCC.TMP; 
H1.DMSC 
 Weak Enhancer 
― CD4.NP; CD8.NP; 
CD34.MBP1480; 
H1.BMP4DM; PANC; 
H1; H9 
 Transcription Enhancer-like 
― GAS  
 Transcription Enhancer-like 
(short gene) 
― PFK.3; HD.CD56MESC 
 TSS-Flanking more 
upstream 
― PFK.2; PFF.1; 
ADI.MSC; MSC.ADIPC; 
 CTCF  
― BJ 
― Caco-2 
― LCL 
― HBMEC 
― HCPEpiC 
― HSMM 
tube 
― HepG2 
― K562 
― MCF-7 
― NHDF-Ad 
― NHEK 
― Osteobl 
 Reduced affinity: 
― LUN1 
 
1f 
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SNP / Gene 
Pathway 
DNaseI Sensitivity Chromatin State TFBS Altered Regulatory 
Motif 
Regulome
DB Score 
HRT.FE; NCC.GED2; 
CD34.MBP1508; 
CCIP.LSMPTP; 
MUS.SC; CD3.P; 
CD34.MBP1562; 
CD34.C; PFM.1,2,3; 
BR.H35; BN.GM2; 
ES.I3; LV; BM.MSC; 
CHON.BMMSC; PAN.I; 
CD4.MP; R.MUC29; 
SK.MUS63; CD15.P; 
NCC.COR2; ADI.NUC; 
CD8.MP; DUO.SMUS 
 TSS Active 
― PFF.2  
 TSS Weak 
― HD.CD184EC 
 TSS Flanking more 
downstream 
― IMR90; R.SMUS; 
SK.MUS; BN-FEO; 
CD34.P; BN.FE1; 
IPS.20; ST.SMUS28; 
COL.SMUS; KID.FE; 
BN.HM150; BN.AG 
DUO.MUC61; BN.CC; 
BN.ITL; BN.MFL; 
BN.SN; HUES48; 
HUES64; HUES6, 
IPS.15; CD34.MBP1549; 
LIV.A; BR.MYO; 
COL.MUC32 
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SNP / Gene 
Pathway 
DNaseI Sensitivity Chromatin State TFBS Altered Regulatory 
Motif 
Regulome
DB Score 
rs7972875 / VPS33A 
Huntington's disease 
 LCL    Reduced affinity: 
― NF-1 
5 
rs1162371 / CEP290 
Olfactory 
transduction 
  Enhancer 
― BN.GM2 
 Weak Enhancer 
― NCC.COR2; 
NCC.GED2; 
BN.MFL; BN.FE1 
  Reduced affinity: 
― STAT3 
6 
rs11104775 / CEP290 
Olfactory 
transduction 
  Enhancer 
― MSC.ADIPCl; 
PFF.2 
 Weak Enhancer 
― Huvec; NHLF; 
ADI.MSC; PFF.1 
  Reduced affinity: 
― CDP_4 
― Dlx2 
 Increased 
affinity: 
― Bsx 
6 
rs11104947 / CEP290 
Olfactory 
transduction 
  Active Enhancer 
― PFF.1 
 Weak Enhancer 
― PFF.2; ADI.MSC 
  
6 
rs10517012 / 
TMEM33 
Olfactory 
transduction 
  Poised Enhancer 
― PFF.1; 
MSC.ADIPC 
 Weak Enhancer 
― LIV.A; ADI.MSC 
  Reduced affinity: 
― HNF4_disc4 
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